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ABSTRACT 
Initiation of the coagulation cascade in vivo is mediated by tissue factor (TF), which 
functions as the cell surface receptor and catalytic cofactor for factor VIIa (FVIIa), as well as the 
mediator for the autoactivation of factor VII (FVII) to FVIIa.  Upon vascular injury, TF is 
exposed to the bloodstream where it comes into contact with FVII(a).  The TF/FVIIa complex 
can be considered as a two-subunit enzyme: TF is the regulatory subunit; and FVIIa is the 
catalytic subunit.  FVIIa does have some proteolytic activity by itself; however, association with 
TF inserted in an appropriate phospholipid bilayer increases its proteolytic activity on 
macromolecular substrates many million-fold.  The mechanisms by which TF enhances the 
activity of FVIIa, and the role of the membrane surface in enhancing catalysis by the TF/FVIIa 
complex are yet not fully understood.  To elucidate the mechanisms of the cell-surface complex 
of TF/FVIIa to trigger the initiation phase of the blood clotting, I investigated how amino acid 
side chain of TF interacted with anionic phospholipids on cell membranes, and how the 
TF/FVIIa complex recognized its protein substrates in the context of the membrane.  
It has been reported that, in vitro, zymogen FVII can be activated to FVIIa via limited 
proteolysis at a single peptide bond by many proteases, including factor Xa, factor IXa, thrombin, 
and factor XIIa, as well as FVIIa in complex with TF.  By using a FVII mutant (S344A), in 
which the active site serine residue has been mutated to alanine, an ongoing project is designed 
to shed light on several unresolved questions regarding FVII activation: 1) which protease plays 
major role in activating FVII during clotting?; 2) what are the influences of various protein 
cofactors on FVII activation?; and 3) where and how are the basal levels of the circulating FVIIa 
generated? 
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CHAPTER 1:  INTRODUCTION 
Overview of blood clotting 
Blood coagulation is the process by which free-flowing blood forms semi-solid, gel-like 
clots to limit further bleeding and begin repairing the damaged vessel.  However, disorders of 
blood coagulation lead to an increased risk of bleeding (hemorrhage) or obstructive clotting 
(thrombosis).  At the macromolecular level, blood clotting is a series of proteolytic events in 
which zymogens of serine proteases are converted into active enzymes, ultimately causing fibrin 
clot formation and platelet activation (1,2). 
There are two main pathways initially described for triggering the blood clotting cascade: 
the contact activation pathway (also known as the intrinsic pathway), and the tissue factor (TF) 
pathway (the extrinsic pathway).  The contact pathway is activated through the contact of blood 
or plasma with an artificial surface, such as clay or glass. It is initiated by the assembly of factor 
XII (FXII), prekallikrein (PK) and high molecular weight kininogen (HK) on anionic polymers 
or surfaces (Fig. 1).  Factor XIIa (FXIIa) is generated, and this then activates factor XI (FXI) to 
XIa (FXIa), which in turn activates factor IX (FIX), resulting in propagation of the clotting 
cascade through the final common pathway.  Though activation of blood clotting by the contact 
pathway has clinical implications in pathologic thrombus formation in humans, it is no longer 
thought to be of primary importance in normal hemostasis. 
The TF pathway is triggered when a nonvascular integral membrane protein, TF, is 
exposed to the bloodstream.  The plasma serine protease, factor VIIa (FVIIa), binds to TF with 
high affinity(Fig. 2).  The resulting TF/FVIIa complex is responsible for activating the 
coagulation cascade in both normal hemostasis and a variety of thrombotic disorders.  As the 
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first enzyme in the clotting cascade, the TF/FVIIa complex occupies a unique position in 
maintaining normal hemostasis, and is the focus of most of this thesis. 
 
Tissue factor  
TF belongs to the class 2 cytokine receptor superfamily (3). As a type I integral 
membrane protein, TF is constitutively expressed on the surface of many extravascular cell-
types, including some epithelial cells, adventitial cells, and keratinocytes (4,5).  The polypeptide 
chain of TF contains either a 261 or a 263 amino acid form, which has a calculated molecular 
weight of 29,447 or 29,593 Da respectively (6-8).  These two forms are in nearly equal 
abundance in the body.  Fully glycosylated TF has an apparent molecular weight of 
approximately 45,000 Da, suggested by the mobility of protein in sodium dodecyl sulfate gel 
electrophoresis (8).   
The TF molecule consists of three domains: an extracellular domain; a single 
transmembrane domain; followed by a cytoplasmic tail (Fig. 3).  The crystal structure of a 
truncated, soluble form of TF (containing only the isolated extracellular domain, termed sTF) has 
been solved by a number of groups (9,10).  The extracellular domain of TF is composed of two 
fibronectin type III domains, which are at roughly 120º from each other in crystal structures.  
The structures of sTF alone or in the complex with FVIIa are very similar, confirming the 
relatively rigid nature of the protein (9,11). The TF ectodomain contains two disulfide bonds, as 
well as three N-linked carbohydrate chains (12,13).  At least one of the disulfide bonds (the 
Cys186-Cys209 disulfide bond) is essential for TF procoagulant activity (14).  Previous studies 
regarding the function of glycosylation on three N-linked carbohydrate chains of TF has been 
controversial.  It has been shown that the ability of the TF/FVIIa complex to activate FX was 
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markedly affected by the presence of the N-linked carbohydrate chains on TF (15).  In contrast, 
Kothari et al. have reported no contribution of any of the three N-linked carbohydrate chains of 
human TF to the ability of TF to transduce intracellular signals, or to TF procoagulant activity 
(16).  This result contradicts the findings of Krudysz-Ambio et al. (15), but is consistent with the 
much earlier report from Paborsky et al. (17), as recombinant TF made in bacteria lacks any 
glycosylation but retains full procoagulant activity.  The single transmembrane domain of TF 
anchors the protein to the cell surface, which is essential for full procoagulant activity of TF.  
However, the exact nature of the membrane anchor appears not to be important.  Full biological 
activity can be restored to the isolated extracellular domain of TF, when TF’s ectodomain fused 
with an oligohistidine tag is used in conjunction with a membrane containing metal-chelating 
lipid (18).  TF has a short cytoplasmic tail made up of 23 amino acids.  Removal of the 
cytoplasmic tail has no detectable effect on the procoagulant activity of TF (19).  The function of 
the cytoplasmic domain is hypothesized to be important in cell signaling, which is reviewed by 
Rao et al. (20).   
As the major physiological activator of blood coagulation, the expression of TF 
throughout the body can be described as forming a functional “hemostatic envelope” around the 
vasculature to prevent excessive bleeding, with relative abundance in areas where the prompt 
prevention of bleeding is critical, such as in the brain, lungs, heart, and skin (4).  TF deficiencies 
have not been described in humans; however, TF knockout mice made via gene targeting are 
reported as resulting in embryonic lethality (21-24).  The phenotype of these embryos includes 
under-developed vasculature, a lack of blood flow, and pools of red blood cells in the yolk sac, 
suggesting that TF also plays an important role in vascular development.  Though complete TF 
knockouts are embryonically lethal, mice have been generated that express roughly 1% of the 
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normal level of the TF gene (25,26).  These mice survive to term and appear outwardly healthy, 
but females tend to undergo fatal postpartum bleeding after pregnancy.  Longer term studies with 
these “low-TF” mice also show they have shortened life spans, suggesting that only a low level 
of TF is compatible with everyday life; however, higher levels of TF are necessary to survive 
hemostatic challenges, traumatic events such as pregnancy, and to sustain a full and healthy life.  
Although TF is essential to life, it is also thought to trigger most thrombotic events (27).  
A number of studies have shown that not only is TF a component of atherosclerotic plaques, but 
that the plaques also demonstrate procoagulant activity (5,28,29).  Plaque disruption is thought to 
initiate TF-mediated thrombus formation leading to myocardial infarction or ischemic stroke.  
Another life-threatening condition is disseminated intravascular coagulation (DIC), in which 
clotting occurs uncontrollably throughout the blood vessels.  Many cases of DIC have been 
associated with elevated TF levels in circulation (30,31).   
 
Factor VIIa 
TF triggers blood clotting by binding to the plasma serine protease zymogen, FVII, and 
the activated form, FVIIa.  FVII is a 50,000 Da trypsin-like serine protease that is synthesized in 
the liver, and then circulates in plasma as a zymogen.  The plasma concentration of FVII is 10 
nM (500 ng/ml), in which roughly 1% of FVII circulates in the active form, FVIIa (32,33).  
Zymogen FVII is a single polypeptide chain of 406 amino acids, converted to FVIIa by limited 
proteolysis at a single peptide bond (Arg152–Ile153).  FVIIa does have some proteolytic activity 
by itself; however, association with TF inserted in an appropriate phospholipid bilayer increases 
its proteolytic activity on macromolecular substrates many million-fold (34,35).   
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FVIIa is composed of a heavy chain and a light chain connected by a disulfide bond.  The 
C-terminal heavy chain is made up of the protease domain containing the His193-Asp242-
Ser344 catalytic triad typical of serine proteases.  The light chain is composed of the N-terminal 
γ-carboxyglutamic acid-rich domain (containing multiple γ-carboxyglutamic acid residues, 
referred to as the Gla domain), the aromatic stack, and two epidermal growth factor (EGF)-like 
domains (Fig. 3).  The Gla domain confers the ability of FVII(a) to bind reversibly, in a calcium-
dependent manner, to negatively charged phospholipids in the membrane surface (36,37).  The γ-
carboxyglutamic acid residues in this domain are converted from glutamic acid residues through 
vitamin K-dependent post-translational modification (38).  Many of the coagulation factors, 
including factor X (FX), FIX and prothrombin, share highly homologous N-terminal Gla 
domains which are essential for activity.  Undercarboxylated proteases containing pre-matured 
Gla domains cannot bind effectively to the membrane surface, and coagulation is diminished.  
FVII can be purified from plasma.  Recombinant FVII has been produced in cultured 
mammalian cells and in the mammary glands of transgenic animals (39)(Patent application 
number: 20110059510).  A factor VII mutant has been produced in which the active site, serine, 
has been mutated to alanine, generating a FVIIa mutant without enzymatic activity.  This has 
been useful in investigating the conversion of FVII to FVIIa (40), which is the main focus of 
chapter four in this thesis. 
 
The complex of tissue factor and factor VII(a) 
Initiation of the coagulation cascade in vivo is mediated by TF, which functions as the 
receptor and catalytic cofactor for FVIIa, as well as the mediator for the autoactivation of FVII to 
FVIIa.  Upon vascular injury, TF is exposed to the bloodstream where it comes into contact with 
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FVII(a).  The TF/FVII complex is activated to TF/FVIIa via cleavage of FVII by thrombin, FXa, 
FIXa, FXIIa, or TF/FVIIa (41-46).  The TF/FVIIa complex can be considered as a two-subunit 
enzyme: TF is the regulatory subunit; and FVIIa is the catalytic subunit.   
The crystal structure of active-site inhibited FVIIa in complex with sTF has been solved 
(11,47).  Within the complex, FVIIa adopts an extended conformation, with its light chain 
wrapping around the relatively rigid framework of sTF (Fig. 3).  The main sites of contact in the 
complex of sTF/FVIIa are located between both fibronectin type III domains of sTF, and the 
EGF1 and protease domains of FVIIa; with minor interactions involving the EGF2 and Gla 
domains of FVIIa.  The Gla domain located at the bottom of the FVIIa molecule is situated near 
the C-terminus of sTF, which is linked to the membrane anchor in intact TF.  Therefore, in the 
view given in Fig. 3, the membrane surface should be located at the bottom of the complex, in 
contact with the Gla domain of FVIIa and the C-terminus region of sTF. 
The interactions between TF and FVIIa have also been studied using domain swapping 
and site-directed mutagenesis (48-51).  Individual amino acids of the TF/FVIIa complex have 
been determined to contribute the binding interactions within the complex, either through 
stabilizing the binding of TF to FVIIa (mainly with the EGF1 domain of FVIIa), or enhancing 
the enzymatic activity of FVIIa (mainly with the protease domain of FVIIa). 
 
Modulation of factor VIIa enzyme activity by tissue factor 
The interactions between TF and FVIIa enhance both the proteolytic and 
amidolytic/esterolytic (i.e., hydrolysis of small, peptidyl-amide or peptidyl-ester substrates) 
activities of FVIIa (34,52).  The mechanisms by which TF enhances the activity of FVIIa, and 
the role of the membrane surface in enhancing catalysis by TF/FVIIa are yet not fully 
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understood.  It is believed that the cofactor function of TF consists of three aspects: 1) TF 
allosterically activates FVIIa via the induction of conformational change within the active site of 
FVIIa; 2) TF tightly binds and rests FVIIa on a phospholipid membrane that is also conducive to 
binding substrates, effectively increasing the concentration of substrates within the vicinity of 
TF/FVIIa; and 3) TF appears to have an extended surface for binding macromolecular substrates 
FIX and FX, known as an exosite.  The combined result of these interactions conferred by TF 
increases the activity of FVIIa many million-fold. 
 
Tissue factor allosterically activates factor VIIa  
The active site of FVIIa in complex with sTF is slightly altered compared to that of free 
FVIIa lacking the Gla domain (11,53,54), suggesting one role of TF is to re-arrange the active 
site residues of FVIIa in order to enhance cleavage of substrates.  Insights into the mechanism of 
allosteric activation of FVIIa have also been obtained by combining site-directed mutagenesis 
and x-ray crystallography studies (55,56), as well as by designing FVIIa variants with enhanced 
enzymatic activity in the absence of TF (57-59). Nevertheless, many questions remain 
unanswered.  A key step in converting FVII to FVIIa happens when the newly generated N-
terminus of FVIIa folds back into the protein to stabilize the active pocket.  It has been 
hypothesized that free FVIIa exists in two states in equilibrium with each other: a catalytically 
active state and a zymogen-like state, depending on whether or not the N-terminus of the FVIIa 
heavy chain is properly folded back into the catalytic domain.  Some experimental data indicate 
that forming a complex with TF shifts the equilibrium to that which favors the catalytically 
active state of FVIIa (60). 
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The role of the membrane in TF/FVIIa activity 
Blood coagulation requires the assembly of several membrane-bound protein complexes, 
including the TF/FVIIa complex.  The membrane surface is important since the rates of FIX and 
FX activation by TF/FVIIa are dramatically increased when TF is incorporated into liposomes 
containing phosphatidylserine (PS) (61).  In physiological conditions, intact cells actively 
sequester negatively charged phospholipids (such as PS and phosphatidic acid (PA)) to the inner 
leaflet of the plasma membrane; but when cells are lysed or damaged, negatively charged 
phospholipids flip from the inner leaflet to the outer leaflet of the membrane (62).  How PS 
augments the enzymatic activity of TF/FVIIa is not completely understood, but much of the rate 
enhancement appears to come from the ability of PS to recruit FIX and FX to the membrane 
surface in the immediate vicinity of TF/FVIIa (63). As mentioned previously, FIX and FX both 
have Gla domains which confer the ability to bind reversibly to negatively charged 
phospholipids in the membrane surface.  The local concentrations of protease and substrate are 
increased, allowing the reaction to occur at a faster rate.   
Tethering both enzyme and substrate to the membrane surface could enhance catalysis by 
doing more than just increasing the local concentration of substrate.  Another postulated 
mechanism for the ability of TF to facilitate the catalytic activity of FVIIa is that TF fixes 
FVIIa’s active site at the correct distance above the membrane surface for optimal engagement of 
the scissile bonds of FIX and FX (64-67).  Fluorescence resonance energy transfer studies show 
that the distance between the active site of membrane-bound FVIIa and the membrane surface is 
shortened from 83 Å to 75 Å upon FVIIa association with TF (64).  Removing the Gla domain of 
FVIIa has little effect on the positioning of the active site of TF/FVIIa relative to the membrane 
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(65).  Thus, TF by itself can fix the location of FVIIa’s protease domain above the membrane 
surface. 
The precise nature of the interactions between TF and the phospholipid membrane, as 
well as the interactions between the TF/FVIIa complex and its substrates on the membrane 
surface, are as yet unknown.  Molecular dynamics simulations of sTF on the membrane surface, 
both alone and in complex with FVIIa, have identified direct interactions between certain sTF 
residues and PS headgroups in a manner that is independent of TF’s transmembrane helix (66).  
Interestingly, the TF residues predicted to interact with PS are located very close to the substrate-
binding exosite region of this protein.  It prompts the hypothesis that PS-interacting residues in 
the TF ectodomain are in allosteric linkage with the nearby exosite region. If so, then interactions 
between TF and PS may promote an exosite conformation that is better able to bind FIX and FX.  
 
The putative substrate-binding exosite on tissue factor  
Previous studies have shown that TF appears to interact with macromolecular substrates, 
FIX and FX, to provide an extended substrate binding site, known as an exosite (50,68,69).  The 
research on the putative exosite has progressed primarily by loss-of-function, site-directed 
mutagenesis studies on TF (70-75).  Several residues have been identified to be important for FX 
and FIX activation by the TF/FVIIa complex (70,71).  These residues are located in the C-
terminal fibronectin type III domain of TF, which are approximate 50-80Å away from FVIIa’s 
active site.  These residues form a continuous solvent-exposed patch (residues Tyr157, Lys159, 
Ser163, Gly164, Lys165, Lys166, Tyr185), and an extended region comprising an additional 7-8 
residues.  The two amino acids in the putative exosite, Lys165 and Lys166, have been 
investigated most thoroughly (72-74).  They are critical for protein substrate recognition by the 
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TF/FVIIa protease complex.  Lys165 and Lys166 contribute to substrate interaction through the 
Gla domains of substrates FX and FIX.  Such interaction may be facilitated by the presence of 
the Gla domain of FVIIa.  However, these TF residues do not affect hydrolysis of small 
substrates by FVIIa.  Previous studies also suggest that Arg200 and Lys201 in the putative 
exosite interact with the EGF1 domain of FX to facilitate optimal docking of substrate FX into 
the catalytic groove of FVIIa (75).  
Even though loss-of-function mutagenesis studies maps a putative exosite in the C-
terminal region of TF, there is no direct evidence for protein substrates binding to the putative 
exosite on TF.  Considering that the Km value for FX activation by TF/FVIIa in solution is ~20 
μM, binding of FX to the TF/FVIIa complex should be relatively weak (52).  In this case, it is 
difficult to evaluate the interactions with the usual binding assays.  Many questions remain 
unanswered, such as the mechanisms for determining substrate recognition and directing the 
action of the enzyme on its biological substrate; the target region of the exosite on the substrate; 
the kinetic and thermodynamic data of binding of substrate to protease complex; and the 
structural evidence for the putative exosite.  Novel approaches would be useful to address these 
questions. 
 
The activation of FVII 
It is been reported that, in vitro, FVII is activated to FVIIa by many proteases, including 
FXa, FIXa, thrombin, and FXIIa, as well as the TF/FVIIa complex (41-46).  It is presently 
unclear which of these proteases plays the major role in activating FVII during clotting, although 
FXa is generally considered as the most likely candidate.  In the studies mentioned above, the 
experimental conditions vary from publication to publication.  Also, the influence of TF on FVII 
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activation by various activators is not clear.  Additionally, some studies utilize activity assays 
focusing on FVIIa amidolytic activity.  However, under those experimental conditions, it is 
unclear if FVII autoactivation by FVIIa in the presence of TF is contributing to the analysis of 
FVII activation by other activators. 
An unusual kinetic mechanism is involved in the autoactivation of FVII regarding 
substrate presentation: the enzyme, FVIIa, is bound to one TF molecule, while the substrate, 
FVII, is bound to a separate TF molecule (45).  The TF/FVIIa and TF/FVII complexes must 
therefore diffuse laterally in the plane of the membrane to encounter each other.  Consequently, 
the reaction rate is governed by the surface density of TF/FVII(a) complexes on the membrane, 
rather than the molar concentrations of any of the reactants. Autoactivation of FVII might be 
important in initiating the clotting cascade, yet its precise role needs further elucidation. 
As mentioned above, approximately 1% of FVII circulates in plasma as activated FVIIa, 
with a half-life of about two hours (32).  These low initial levels of FVIIa are thought to trigger 
the clotting cascade upon exposure to TF, and to back-activate the rest of the zymogen, FVII, by 
downstream proteases.  One question that remains to be solved is where and how basal levels of 
FVIIa in circulation were generated. Findings from several studies suggest that the formation of 
the circulating FVIIa found in plasma may occur on lipoprotein particles, apparently involving 
FIX (presumably as FIXa) (76,77).   
 
Scope of this thesis 
Tight regulation of the hemostatic system is necessary; otherwise the consequences are 
critical and usually fatal.  TF has the unique position of being the only member of the 
coagulation cascade sequestered outside of the vasculature and being responsible for triggering 
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the coagulation cascade.  All of the serine proteases and most protein cofactors circulate in the 
plasma as inert precursors and require additional proteolysis.  TF is a notable exception.  These 
make TF an important target in regulating hemostasis.  The primary focus of this thesis is to 
understand how the initiation phase of the blood clotting system is triggered by the cell-surface 
complex of TF and FVIIa.   
This first chapter serves as a brief introduction to blood coagulation and the TF/FVIIa 
complex.  In chapter two, I describe how individual amino acid side chain of TF interacts with 
anionic phospholipids on cell membranes.  Diminished procoagulant activity of several TF 
mutants is restored by increasing the PS content of liposomes, suggesting that residues in the TF 
ectodomain may come into direct contact with PS to enhance its cofactor activity.  These results 
are consistent with the role of protein-phospholipid interactions as a critical regulatory 
mechanism in blood clotting.  In chapter three, I investigate the notion that TF contains an 
exosite which directly binds to protein substrates and assists with substrate recognition.  To 
investigate the interactions between TF exosite and protein substrates, FIX and FX, stable 
TF/FVIIa/FX and TF/FVIIa/FIX complexes are generated.  This is accomplished via selecting 
gain-of-function TF mutants which enhance the binding affinities of TF mutants to protein 
substrates, FX and FIX.  Chapter four is devoted to analyzing how zymogen FVII is converted to 
the active serine protease, FVIIa, by various potential activators.  A form of FIXa that lacks 
procoagulant activity is nevertheless a potent activator of FVIIa.  These results may help explain 
the presence of low but significant levels of FVIIa in all individuals, which may be essential in 
triggering blood clotting following vascular injury.  Overall, the work of this thesis aids in 
elucidating the importance of the assembly of protease to specific protein cofactor on suitable 
membrane surfaces.  
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FIGURES 
 
 
FIGURE 1.  Simplified contact pathway of coagulation.  The contact coagulation pathway is initiated 
by negatively charged surfaces that support reciprocal activation of FXII to FXIIa, and PK to kallikrein, 
requiring the cofactor, HK.  FXIIa converts FXI to FXIa, which converts FIX to FIXa.  FIXa and its 
cofactor FVIIIa convert FX to FXa, which is where the contact and TF pathways converge. 
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FIGURE 2.  Simplified TF pathway of coagulation.  The TF coagulation pathway is initiated by the 
formation of the TF/FVIIa complex.  This complex can convert FX to FXa, and FIX to FIXa.  FIXa binds 
to its cofactor FVIIIa to convert more FX to FXa.  FXa binds to its cofactor FVa to convert prothrombin 
to thrombin.  Thrombin converts fibrinogen to fibrin, which polymerizes to form fibrin clot.  In addition, 
thrombin is a potent activator of platelets. 
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FIGURE 3.  The TF/FVIIa complex.  The crystal structure of the sTF/FVIIa complex is shown with a 
cartoon depiction of the transmembrane and cytoplasmic domains of TF, as well as the phospholipid 
bilayer. TF (in blue) binds to FVIIa with major interactions between the extracellular domain of TF and 
EGF1 and protease domains of FVIIa. The Gla domain of FVIIa is situated near the membrane surface. 
This crystal structure is prepared from coordinates from the Protein Data Bank structure 1DAN (11). 
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CHAPTER 2: INTERACTION OF TISSUE FACTOR WITH 
MEMBRANE PHOSPHOLIPIDS 
ABSTRACT 
Blood clotting is initiated by the two-subunit enzyme consisting of the plasma protease, 
factor VIIa (FVIIa, the catalytic subunit), bound to the integral membrane protein, tissue factor 
(TF, the regulatory subunit).  Molecular dynamics simulations have predicted that certain 
residues in the TF ectodomain interact with phosphatidylserine headgroups to ensure optimal 
positioning of the TF/FVIIa complex relative to its membrane-bound protein substrates, factors 
IX (FIX) and X (FX).  In this study, we individually mutated to alanine all the putative 
phosphatidylserine-interactive residues in the TF ectodomain and measured their effects on TF 
cofactor function (activation of FIX and FX by TF/FVIIa, and clotting of plasma).  Some TF 
mutants exhibited decreased activity in all three assays, with the most profound defects observed 
from mutations in or near the flexible loop from Lys159 to Gly164.  The decreased activity of all 
of these TF mutants could be partially or completely overcome by increasing the 
phosphatidylserine content of TF-liposomes.  Additionally, yeast surface display was used to 
screen a random library of TF mutants for enhanced FVIIa binding.  Surprisingly, mutations at a 
single amino acid (Lys165) predominated, with the Lys165→Glu mutant exhibiting a 3-fold 
enhancement in FVIIa binding affinity.  Our studies reveal residues in the C-terminal half of the 
TF ectodomain which may interact directly with phosphatidylserine headgroups to enhance TF 
cofactor activity, possibly by allosterically modulating the conformation of the adjacent 
substrate-binding exosite region of TF. 
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INTRODUCTION 
Tissue factor (TF), an integral membrane protein, initiates the blood clotting cascade by 
functioning as the cell-surface receptor and essential protein cofactor for the plasma serine 
protease, factor VIIa (FVIIa) (1,2).  The resulting TF/FVIIa complex activates factors IX (FIX) 
and X (FX) by limited proteolysis (3).  Multiple mechanisms contribute to the dramatic increase 
in the catalytic activity of FVIIa when it binds to TF.  One effect of TF is to allosterically 
activate FVIIa, shifting its protease domain from a zymogen-like state to a fully active serine 
protease (4).  This process is independent of the membrane (5).  Another contribution to catalysis 
is the presence of a substrate-binding site (exosite) on TF that assists FVIIa to recognize FIX and 
FX as substrates (6-9).  The TF exosite was identified through mutagenesis studies and its 
location in the TF/FVIIa complex is far from FVIIa’s active site.  The previous two mechanisms 
are based on protein-protein interactions, but the membrane is also important since the rates of 
FIX and FX activation by TF/FVIIa are dramatically increased when TF is incorporated into 
liposomes containing phosphatidylserine (PS) (10).  Much of this rate enhancement appears to 
come from the ability of PS to recruit FIX and FX to the membrane surface in the immediate 
vicinity of TF/FVIIa (11). 
Yet another postulated mechanism for the ability of TF to the catalytic activity of FVIIa 
is that TF fixes FVIIa’s active site at the correct distance above the membrane surface for 
optimal engagement of the scissile bonds of FIX and FX (12-15).  Removing the membrane-
binding domain of FVIIa (its γ-carboxyglutamate-rich domain, or Gla domain) has little effect on 
the positioning of the active site of TF/FVIIa relative to the membrane.  Thus, TF by itself can 
fix the location of FVIIa’s protease domain above the membrane surface (13). 
The precise nature of the interactions between TF and the phospholipid membrane, as 
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well as the interactions between the TF/FVIIa complex and its substrates on the membrane 
surface, are as yet unknown.  Molecular dynamics simulations of the TF ectodomain (termed 
soluble TF, or sTF) on the membrane surface, both alone and in complex with FVIIa, have 
identified direct interactions between certain sTF residues and PS headgroups in a manner that is 
independent of TF’s transmembrane helix (14).  Interestingly, the TF residues predicted to 
interact with PS are located very close to the substrate-binding exosite region of this protein.  
This prompted us to hypothesize that PS-interacting residues in the TF ectodomain are in 
allosteric linkage with the nearby exosite region.  If so, then interactions between TF and PS may 
promote an exosite conformation that is better able to bind FIX and FX. 
In this study, we used mutagenesis to examine how TF residues that are predicted to 
interact with PS contribute to the proteolytic activity of the TF/FVIIa complex.  We also used 
yeast surface display to select TF mutants with enhanced binding affinity to FVIIa, with 
surprising results.  Our findings are consistent with the notion that conformational changes in TF, 
induced upon binding to both FVIIa and PS, may help regulate the catalytic activity of TF/FVIIa 
on membrane surfaces. 
 
EXPERIMENTAL PROCEDURES 
Materials 
Materials were from the following suppliers: pooled, citrated normal human plasma, 
George King Bio-Medical (Overland Park, KS); porcine brain PS and egg phosphatidylcholine 
(PC), Avanti Polar Lipids (Alabaster, AL); recombinant human FVIIa, American Diagnostica 
(Greenwich, CT); human plasma FIX and FX, Enzyme Research Laboratories (South Bend, IN); 
and fluorescein-Phe-Pro-Arg-chloromethylketone (fl-FPRck), Haematologic Technologies, Inc. 
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(Essex Junction, VT).  Fl-FVIIa was prepared by reacting FVIIa to completion with fl-FPRck 
(confirmed by loss of enzymatic activity), after which excess inhibitor was removed by dialysis. 
 
Recombinant membrane-anchored TF 
Membrane-anchored human TF (membTF) was expressed in E. coli and purified as 
described (16); it consisted of amino acids 3-244 (17).  Purified membTF was incorporated into 
liposomes of varying phospholipid composition as described previously (18), using Bio-Beads® 
SM-2 and 20 mM sodium deoxycholate.  The molar ratio of membTF to total phospholipid was 
about 1:8700.  The concentration of available TF on the outside of the liposomes was quantified 
by titration with FVIIa as described previously (5).  Concentrations of membTF in liposomes 
were reported here as the available TF concentrations. 
 
FX activation 
Initial rates of FX activation by TF/FVIIa were quantified in a two-stage assay as 
described (19), with the following modifications.  In the first stage, relipidated membTF and 
FVIIa were first incubated for 5 min in HBSAC buffer (25 mM HEPES pH 7.4, 100 mM NaCl, 5 
mM CaCl2, 0.1% BSA, 0.1% NaN3), after which FX was added.  Reactant concentrations were 
as follows.  For membTF-liposomes without PS: 100 pM FVIIa, 2 nM membTF and 100 nM FX; 
for membTF-liposomes with PS: 5 pM FVIIa, 100 pM membTF and 100 nM FX.  Timed 10 µl 
aliquots, over a 10 min period, were removed and quenched in 25 µl Stop Buffer (60 mM Mes-
NaOH pH 5.8, 75 mM EDTA, 50 mM NaCl, 8% Lubrol PX).  In the second stage, FXa 
concentrations were measured by adding 10 µl 2.0 M Tricine-NaOH (pH 8.4) and 50 µl 1 mM 
Spectrozyme FXa (chromogenic substrate), then measuring the increase in A405.  Rates of FXa 
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generation supported by membTF mutants were expressed as percent of the activity observed 
with wild-type membTF with the same phospholipid composition. 
 
FIX activation 
Initial rates of FIX activation by TF/FVIIa were quantified by a modification of the 
method for FX.  In the first stage, reactant concentrations were: 5 nM FVIIa, 50 nM membTF 
and 800 nM FIX for membTF-liposomes without PS; and 150 pM FVIIa, 1.5 nM membTF and 
800 nM FIX for membTF-liposomes with PS.  Timed 40 µl aliquots were sampled up to 40 min, 
and quenched in 20 µl Stop Buffer.  In the second stage, FIXa concentrations were measured by 
adding 10 µl 2.0 M Tricine-NaOH (pH 8.4) and 50 µl CBS 31.39 substrate (Diagnostica Stago, 
Parsippany, NJ) containing 33% ethylene glycol as described (20).  Rates of FIXa generation 
were normalized to rates observed with wild-type membTF, as with the FXa generation assays. 
 
Clotting assay 
Clotting assays were carried out in a ST4 coagulometer (Diagnostica Stago, Parsippany, 
NJ) as described (21).  One unit of TF procoagulant activity is defined as the TF concentration 
yielding a 50 s clot time with pooled normal plasma.  Specific procoagulant activities of 
membTF mutants were compared by reference to a standard curve of clotting times using wild-
type membTF-liposomes of the same phospholipid composition. 
 
Yeast surface display 
A random library of mutant sTF cDNAs was prepared essentially as described (22).  
Briefly, random nucleotide errors were incorporated into the sTF coding sequence using Taq 
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polymerase (Invitrogen, Carlsbad, CA) with 0.5 mM MnCl2 and 2 mM MgCl2 to achieve a 0.3% 
error rate, then cloned into the pCT302 yeast display vector by homologous recombination.  
Transformed EBY100 yeast were grown in SD-CAA medium (2% dextrose, 0.67% yeast 
nitrogen base, 1% casamino acids) at 30°C for 48 h; sTF expression was then induced in SG-
CAA medium (2% galactose, 0.67% yeast nitrogen base, 1% casamino acids) at 20°C for 18-20 
h (22,23).  After incubating the yeast cells with a fluorescently-labeled anti-TF monoclonal 
antibody (TF9-5B7), a high level of expression of sTF on the yeast surface was confirmed by 
flow cytometry.  TF-expressing yeast cells were incubated with 8 nM fl-FVIIa for 40 min, 
washed briefly with HBSAC, and then sorted in purification mode using a MoFlo cell sorter 
(DakoCytomation, Ft. Collins, CO) with an event rate of ~50,000 cells/s (22,24).  A total of 
5×107 cells were examined during the first sorting round, from which the top ~0.5% of the 
population with the highest fl-FVIIa binding signal was collected and cultured at 30°C in SD-
CAA, followed by induction in SG-CAA to induce protein expression.  After four additional 
rounds of sorting with fl-FVIIa and growth, the sorted cells were plated on selective glucose 
medium to isolate individual clones.  Plasmids were rescued from isolated yeast clones using a 
Zymoprep miniprep kit (Zymo Research, Orange, CA) and subjected to DNA sequencing.  A 
representative sTF mutant containing the Lys165→Glu mutation was cloned in E. coli, expressed 
and purified as described (16). 
 
Surface plasmon resonance (SPR) analyses 
The FVIIa binding affinities of mutant and wild-type sTF were determined at 25°C using 
a Biacore 3000 SPR instrument (GE Healthcare, Pittsburgh, PA).  The calcium-dependent HPC4 
antibody was bound to CM5 sensorchips by standard amine coupling; after blocking and 
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washing, sTF molecules containing the HPC4 epitope tag at their N-termini (25) were captured 
on the surface.  The affinity of FVIIa for sTF was calculated from the kinetics of binding to 
immobilized sTF as described (26), with the following modifications.  We determined koff by 
analyzing the response curve observed upon return to buffer flow after saturation with 40 μL of 
50 nM FVIIa.  Association rate constants (ks) were calculated by using a series of six FVIIa 
concentrations ranging from 6 nM to 100 nM, and kon was determined from the concentration 
dependence of ks.  Kinetics measurements commonly employed a flow rate of 15 μL/min, and 
sensor chips were regenerated by injecting 50 mM EDTA between runs.  Kinetic constants were 
determined by nonlinear regression analysis as described (27). Stand errors reported were from 
the plot fit. 
 
RESULTS AND DISCUSSION 
Effects of TF mutations on FVIIa-dependent activation of FIX and FX 
Based on previous molecular dynamics simulations of interactions between phospholipid 
bilayers and sTF, alone or in complex with FVIIa (14), twenty surface-exposed residues in the C-
terminal half of the TF ectodomain were selected for mutagenesis.  This included all eighteen 
residues identified in the simulations as interacting with PS headgroups, plus adjacent residues 
G164 and K165 (listed in Table 1).  The mutants and wild type were expressed as membTF, 
purified and incorporated into liposomes containing 0 to 30% PS (balance = PC).  FVIIa was 
then bound to relipidated membTF and initial rates of FIX and FX activation were measured.  
Table 1 reports the normalized initial rates of FX activation (as percent of wild-type) for all 
twenty mutants in 5% PS/95% PC liposomes.  Table 1 also summarizes results from previously 
published studies of these twenty mutants, where available.  In our hands, twelve of the mutants 
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(Q118A, V119A, G120A, T121A, K122A, S161A, K181A, G182A, E183A, N184A, Q212A 
and E213A) supported FX activation rates that were ≥ 70% of that of wild-type membTF, and 
were not studied further.  To our knowledge, the effects of mutating these twelve residues on 
TF/FVIIa proteolytic activity have not previously been reported, except for mutation of residue 
S161 which, in agreement with this study, was reported not to decrease TF activity (28). 
We next examined, in detail, the properties of the eight membTF mutants whose FX 
activation rates were found to be <70% of that of wild-type membTF (indicated in boldface in 
Table 1).  When incorporated into liposomes containing either 100% PC or 5% PS/95% PC, five 
of these mutants (K159A, S163A, G164A, K165A, and K166A) supported rates of FX activation 
that were <30% of wild type, while the other three (S160A, S162A, D180A) supported rates that 
were 30-70% of wild type (Fig. 4A).  The decreased FX activation rates were ameliorated by 
increasing the PS content of liposomes.  In fact, for all but the D180A mutant there was a linear 
relationship between the relative activities of these mutants and PS content, over the range of 0 
to 30% PS.  Since the rates are normalized to wild-type, our results indicate that PS enhances the 
cofactor activity of all eight TF mutants to an even greater degree than for wild-type TF.  
Mutants S162A and K165A exhibited steeper slopes than the others, indicating that their 
activities may be especially sensitive to increasing PS content in the proteoliposomes. 
To our knowledge, the effects of five of these eight TF mutations on FVIIa-dependent FX 
activation have previously been tested by others (i.e., all but S160A, S162A and D180A; Table 
1).  There was general agreement between our findings and the previous studies, with the 
exception of the report that the K159A mutation had essentially 100% activity (28), while we 
found a significant deficiency in FX activation caused by this mutation.  It should be noted, 
however, that the previous mutational studies of TF typically employed detergent lysates of 
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whole, transfected cells as the source of membrane-anchored TF activity (see Table 1, footnotes), 
so the actual membrane compositions of the TF preparations used in those studies were unknown 
and not controlled.  An exception was the study of Kirchhofer et al. (6), but it used sTF instead 
of membrane-anchored TF, which also renders direct comparisons with our findings difficult. 
We found that all eight membTF mutants that we chose for more intensive study also 
supported reduced rates of FIX activation, with similar reductions relative to their effects on FX 
activation (Fig. 4B and C; and Table 1).  As with FX activation, increasing the PS content of the 
liposomes over the range of 0 to 30% PS increased the rate of FIX activation supported by these 
membTF mutants.  Four of them (K159A, S163A, G164A and D180A) exhibited linear 
relationships between relative cofactor activity and PS content, while the other four (S160A, 
S162A, K165A and K166A) exhibited a relationship that was not strictly linear, appearing to 
saturate above 20% PS.  There was general agreement between our findings and previous studies 
of five of these mutations (Table 1), with the same caveats, however, about interpretation owing 
to the vastly different phospholipid compositions used in those studies relative to the present 
study. 
 
Effects of TF mutations in plasma clotting assays  
Plasma clotting assays were employed to examine the procoagulant activities of membTF 
mutants.  By their nature, clotting assays test for additional functions of TF compared to assays 
with purified proteins; importantly, this includes the requirement that TF promote the conversion 
of zymogen FVII to FVIIa (29).  Also, clotting assays are performed under non-equilibrium 
conditions, so altering the rates of formation of protein-protein and protein-membrane complexes 
can have an impact on measured clotting times.  Accordingly, the eight membTF mutants studied 
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in Fig. 4 were incorporated into liposomes containing 5, 20 or 30% PS (balance = PC) and their 
clotting activities were measured, normalized to the activity of wild-type membTF at the same 
phospholipid composition (Fig. 5A).  These eight membTF mutants were typically more deficient 
in clotting activity than they were in supporting FIX or FX activation by purified TF/FVIIa 
complexes.  This was especially for membTF in liposomes with 5% PS, in which all eight 
mutants had low activity and in which five (K159A, S163A, G164A, K165A and K166A) had 
little or no clotting activity.  As with the assays of FIX and FX activation using purified proteins, 
raising the PS content of the membTF-liposomes to 20 or 30% PS substantially increased the 
plasma clotting activity of the mutants relative, to wild-type TF. 
The effects of seven of these mutations (i.e., all but D180A) on TF clotting activity have 
been reported by others, with, in general, the previously reported plasma clotting activities being 
substantially higher than we observed in this study (Table 1).  However, the very different 
membrane compositions used in the prior studies make comparisons with our findings difficult. 
One of the functions of TF is to promote the rapid conversion of zymogen FVII to FVIIa 
during clotting reactions.  If this function were deficient in the mutants, it could contribute to 
their reduced procoagulant activities when tested with normal human plasma, which contains 
only trace levels of pre-formed FVIIa (30).  In order to eliminate the contribution of FVII 
activation from clotting assays, we added 10 nM FVIIa to normal human plasma, thus bypassing 
the need for TF to promote the conversion of FVII to FVIIa.  Under these conditions (Fig. 5B), 
the specific procoagulant activities of membTF mutants showed a similar pattern compared with 
those measured without added FVIIa, although the relative activities in all cases were somewhat 
higher than when tested in the absence of added FVIIa.  This finding suggests that the mutants 
may have some deficiency in supporting the conversion of FVII to FVIIa during clotting 
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reactions, but that this alone cannot explain their reduced clotting activities.  As before, the 
relative specific procoagulant activities of the membTF mutants increased with increasing PS 
content in the liposomes. 
 
Location of putative lipid-interacting residues in the crystal structure of the TF ectodomain 
The TF residues examined in this study are color-coded in the crystal structure of sTF in 
Fig. 6.  The previously identified membrane-interactive residues of sTF alone (Fig. 6A), or of 
sTF in complex with FVIIa (Fig. 6B), are colored based on the fraction of time they were found 
to maintain contact with PS headgroups during the molecular dynamics simulations: green for 
<30% of the time, blue for 30-70%, and red for >70% (14).  In comparison, Fig. 6C shows the 
TF residues mutated in this study, colored in three groups according to their relative deficiencies 
in FVIIa-dependent FX activation when assayed using membTF in 5% PS/95% PC liposomes: 
<30% wild-type activity = red; 30-70% wild-type activity = blue; >70% wild-type activity = 
green. 
In the molecular dynamics simulations, the angle of sTF relative to the membrane surface 
was altered when sTF complexed with FVIIa (14).  This leaning motion of sTF is readily 
appreciated by comparing the membrane contact probabilities of residues in sTF alone (Fig. 6A) 
with those in sTF complexed with FVIIa (Fig. 6B).  Further comparing these membrane 
footprints with the pattern of TF residues whose mutations were found to decrease FX activation 
(Fig. 6C), may give insights into the arrangement of the TF ectodomain within the TF/FVIIa/FX 
complex (whose structure is currently unknown) on the membrane surface.  The most profound 
defects in FX activation were exhibited by mutations (colored red in Fig. 6C) in or near the 
flexible loop of TF from Lys159 to Gly164, which lacks interpretable electron density in most 
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published sTF crystal structures (31,32).  Interestingly, this region has been proposed to be an 
important part of the putative exosite of TF (6-9).  Residues Lys165 and Lys166 in particular are 
strongly suspected to interact directly with the substrates FX and FIX, in a manner that requires 
the presence of the Gla domain on the substrate (33).  These TF residues lie at the very “bottom” 
of the C-terminal half of the TF ectodomain, and therefore should be adjacent to the membrane 
surface.  We speculate that, by interacting directly with phospholipid headgroups, this flexible 
loop and the nearby exosite region of TF are induced to undergo conformational changes that 
create an exosite conformation favorable for docking protein substrates like FX and IX.  The 
mutations in our study may weaken this interaction between TF and the membrane, a deficiency 
that could be partially to fully overcome (depending on the precise mutation) simply by 
increasing the PS content of the membTF-liposomes. 
 
Selection of TF mutants with enhanced FVIIa affinity 
To further investigate the nature of allosteric interactions between TF with FVIIa, TF 
mutants were selected to achieve enhanced binding affinity for FVIIa.  A randomly-mutated sTF 
library was displayed on the surface of yeast, and five cycles of flow cytometry using relatively 
low concentrations of fl-FVIIa was used to select sTF mutants with increased FVIIa binding.  A 
significant enrichment in the FVIIa-positive population was observed by the fifth sorting, after 
which 37 yeast clones were isolated and their sTF cDNAs sequenced, resulting in 29 unique sTF 
DNA sequences containing a total of 75 non-silent mutations.  Surprisingly, mutations at a single 
residue, Lys165, dominated the collection of sTF mutants (Fig. 7).  Thus, 22 of the 29 unique 
sTF sequences were mutated at this Lys residue, with substitutions of just two amino acids, Glu 
(10 mutants) and Met (11 mutants), predominating.  This is especially interesting since Lys165 is 
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part of the exosite region of TF that is proposed to function in recognizing FIX and FX as 
substrates by the TF/FVIIa complex (6).  We determined the effect of mutating this TF residue to 
Glu on FVIIa binding affinity, as quantified by surface plasmon resonance (Fig. 8).  FVIIa 
binding to wild-type sTF had kon = 2.68 (±0.001) × 105 M−1 s−1 and koff = 3.63 (±0.12) × 10-3 s−1, 
with a calculated Kd of 13.5 ± 0.4 nM.  The sTF mutant K165E had an enhanced binding affinity, 
with very similar kon (2.95 (±0.003) × 105 M−1 s−1) but a slower koff (1.29 (±0.007) × 10-3 s−1) and 
lower Kd (4.4 ± 0.02 nM).  This threefold enhancement in FVIIa binding affinity for the K165E 
mutant is consistent with our previous study which showed about a twofold enhancement in 
binding affinity for the K165E,K166E double mutant relative to wild-type sTF (33).  
Interestingly, however, mutating these two Lys residues to Ala was without effect on FVIIa 
binding affinity (33).  
The dominance of two amino acid substitutions at a single TF residue following selection 
for increased FVIIa binding was surprising, especially coupled with the fact that K165 was one 
of the first residues whose chemical modification and mutation identified the exosite region of 
TF (34).  This residue is also highly conserved among mammalian TF sequences.  Thus, it 
appears there is an energy penalty associated with the presence of K165 when TF binds to FVIIa, 
which is ameliorated when this Lys is mutated to Glu.  We speculate that the energy penalty 
associated with K165 upon association of TF with FVIIa is coupled to a conformational change 
in the adjacent exosite region of TF.  Thus, mutating this residue to Glu may simultaneously 
increase the affinity of sTF for FVIIa and diminish the function of the TF exosite region, via 
disabling the proposed FVIIa binding-induced conformational change in TF. 
We found that increasing the PS content of membTF-liposomes partially or completely 
overcame the decreased TF activity of mutations in or near the exosite region, possibly by 
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stabilizing the interaction of this part of the TF with the membrane surface and thereby 
optimizing the interaction of the TF/FVIIa complex with its membrane-bound substrates, FIX 
and FX.  This finding is similar to previous findings that the deleterious effects of mutations of 
TF exosite residues K165 and K166 can also be overcome, to some extent, by increasing the PS 
content of TF-liposomes (33,35).  Thus we postulate an allosteric linkage between the interaction 
of TF with PS and the conformation of the nearby TF exosite.  The ability of increasing the PS 
content of TF-liposomes to restore the activity of the TF/FVIIa complex in our mutants may be 
due to multiple, relatively weak phospholipid binding interactions with the TF ectodomain.  
Thus, mutations which decrease the affinity of this part of TF for the membrane bilayer may 
require higher concentrations of PS in liposomes to saturate the binding interactions between the 
TF ectodomain and PS headgroups.  Other explanations are also possible, however, including 
effects of elevated PS on the Gla domains of the enzyme (FVIIa) and/or its protein substrates 
(FIX and FIX) to compensate for the effects of the TF mutants.  It should be pointed out that the 
putative exosite region of TF has only been characterized, to date, only via mutagenesis studies.  
Thus, to our knowledge, direct binding of FIX or FX to this or any other region of TF has not 
been demonstrated experimentally.  Direct physical studies of the TF/FVIIa/FIX or 
TF/FVIIa/FIX complexes, possibly including solving crystal structures of such trimolecular 
complexes but more preferably studies conducted in the context of their assembly on PS-
containing membrane bilayers, are needed to address these questions in more detail. 
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TABLES AND FIGURES 
TABLE 1.Ability of membTF mutants to support activation of FX and FIX, and clotting of plasma. 
TF Mutant FX activation  FIX activation  Clotting activity 
This studya Literature  This studya Literature  This studya Literature 
Q118A 97%   — b  — b 
V119A 98%   — b  — b 
G120A 101%   — b  — b 
T121A 90%   — b  — b 
K122A 93%   — b  — b 
K159A 24 ± 3.2% <30% c; ~100% d  28 ± 2.9% 30-75% c  3 ± 1% 8%e; ~5% d 
S160A 66 ± 3.6%   58 ± 5.1%  24 ± 8% 95% e 
S161A 114%   — b  — b 128%d 
S162A 53 ± 1.3%   54 ± 4.4%  16 ± 3% 82% d 
S163A 5 ± 0.7% <30% c  8.7 ± 1.1% <30% c  0.20 ± 0.08% 11% d 
G164A 5 ± 0.5% <30% c  10 ± 1.4% <30% c  0.20 ± 0.10% 3% d 
K165A 14 ± 0.7% 17% f; <30% c  21 ± 1.8% <30% c  1.2 ± 0.05% 30% g 
K166A 6.4 ± 0.5% 5% f; <30% c  14 ± 1.5% <30% c  0.30 ± 0.09% 12% g 
D180A 64 ± 10%  67 ± 15%  20 ± 8% 
K181A 139%  — b  — b 
G182A 82 ± 3.8%  — b  — b 
E183A 137%  — b  — b 
N184A 79 ± 6.0%  — b  — b 
Q212A 87 ± 9.3%  — b  — b 
E213A 82 ± 12%  76 ± 9.3%  — b 
aFor this study, data are mean ± standard deviation of rates of FX and FIX activation, and clotting 
activities, using membTF mutants in 5% PS/95% PC vesicles, as percent of activity with wild-type 
membTF. The eight mutants selected for more intensive study are boldfaced. 
bNot determined. 
cKirchhofer et al. (6), using purified sTF in the presence of either SW-13 cell membranes or 500 µM 70% 
PS/30% PC liposomes. 
dRuf et al. (28), using detergent (n-octyl-β-D-glucopyranoside) lysates of Chinese hamster ovary cells 
transfected to express membrane-anchored TF. 
eRehemtulla et al. (36), using detergent (Triton X-100) lysates of Chinese hamster ovary cells transfected 
to express membrane-anchored TF. 
fRoy et al. (34), using detergent (Triton X-100) lysates of human kidney 293 cells transfected to express 
membrane-anchored TF, which were then diluted in a relipidation buffer containing 100% PC vesicles. 
gRuf et al. , using detergent (n-octyl-β-D-glucopyranoside) lysates of Chinese hamster ovary cells 
transfected to express membrane-anchored TF.   
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FIGURE 4. PS dependence of the effects of membTF mutations on FVIIa-dependent FX and FIX 
activation. Initial rates were quantified for activation of FX (A) or FIX (B,C) by FVIIa bound to membTF 
mutants that had been incorporated into liposomes of the indicated mol% PS (balance = PC). Data are 
normalized to the activity of wild-type membTF at the same PS content. Solid lines were plotted if they fit 
the data with an r2 ≥ 0.95. Dashed lines were used to connect data points if an attempt to fit a line yielded 
an r2< 0.95. For clarity, the solid and dashed lines for FIX activation are plotted in separate panels (B and 
C). Data in all panels are mean ± SD, n = 3. 
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FIGURE 5. Procoagulant activities of membTF mutants. Clotting times of citrated, pooled normal 
plasma, with no added FVIIa (A) or with 10 nM added FVIIa (B), were quantified in clotting assays 
triggered by addition of calcium ions plus relipidated wild-type or mutant membTF. The membTF-
liposomes contained 5% PS (solid bars), 20% PS (hatched bars) or 30% PS (gray bars), with the balance 
being PC. Specific procoagulant activities of the mutants are plotted as percent of the specific activity of 
wild-type membTF-liposomes of the same phospholipid composition. Data are mean ± SD, n = 2 or 3. 
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FIGURE 6. TF residues that putatively interact with PS. Shown is the crystal structure of sTF (Protein 
Data Bank file 1BOY (37)), arranged so that the portion of the TF ectodomain proposed to interact with 
the membrane is facing the viewer. In A and B, TF residues are colored based on the percentage of the 
time they were directly interacting with PS in molecular dynamics simulations (14): green, <30% of the 
time; blue, 30-70% of the time; and red, >70% of the time. Panel A is from simulations of sTF alone on 
the membrane, and panel B from simulations of the sTF/FVIIa complex on the membrane. C, TF residues 
are colored according to their effects, when mutated to Ala, on rates of FVIIa-dependent FX activation 
using membTF-liposomes with 5% PS/95% PC (data from this study, as percent of wild-type activity): 
red, <30%; blue, 30-70%; and green, >70%.  
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FIGURE 7. TF mutants selected by yeast surface display for enhanced FVIIa binding. After random 
mutagenesis, sTF mutants were expressed on the surface of yeast cells and selected for increased FVIIa 
binding as described in EXPERIMENTAL PROCEDURES. 37 clones were sequenced and the 
frequencies of the resulting mutations are plotted by residue number. The actual number of observed 
amino acid substitutions by amino acid type are indicated on the graph for residues K165, K166 and 
M210. 
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FIGURE 8. SPR measurements of FVIIa binding to immobilized sTF. A, Resonance Units (RU) 
obtained when 6 to 100 nM FVIIa was flowed over immobilized sTF on sensorchips. B, concentration 
dependence of ks values determined by nonlinear regression analysis of the association data from A (from 
0-160 s). The solid line is linear least-squares fit of the equation ks = konC + koff, where C is the 
concentration of free FVIIa. C, sensorgram (solid line) observed for dissociation following injection of 50 
nM FVIIa; the dashed line is the result of nonlinear regression analysis using a single-exponential decay. 
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CHAPTER 3: TISSUE FACTOR VARIANTS WITH ENHANCED BINDING  
AFFINITY FOR PROTEIN SUBSTRATES 
ABSTRACT 
Tissue factor (TF) initiates the blood clotting cascade by functioning as the cell-surface 
receptor and essential protein cofactor for the plasma serine protease, factor VIIa (FVIIa).  It has 
been proposed that TF contains exosites which directly interact with the protein substrates, 
factors X (FX) and IX (FIX), thereby assisting with the substrate recognition by FVIIa.  In this 
study, gain-of-function TF mutants were selected in which the resulting TF/FVIIa complexes had 
enhanced affinities for the protein substrate, FX, while retaining FVIIa binding and enzymatic 
activity.  Yeast surface display technique was used as a platform for expressing a random library 
of mutant soluble TF (sTF) cDNAs which was then subjected to fluorescence-activated cell 
sorting via flow cytometry.  The results of selected TF mutants fell mainly into 3 groups, with 
multiple identical clones in each group.  Flow cytometry-based binding methods estimated the 
apparent Kd values for protein substrates binding to sTF/FVIIa on yeast surface.  The results 
showed that representative sTF mutants from all three groups had significantly reduced apparent 
Kd values for both FX and FIX binding, with respect to the sTF wild-type values.  Furthermore, 
these sTF mutants showed comparable Km and kcat values relative to wild-type sTF in supporting 
the activation of FX by FVIIa in solution, which demonstrated that the selected TF mutants 
retained productive binding of FX.  The formation of stable TF/FVIIa/FIX and TF/FVIIa/FX 
ternary complexes would be useful for a variety of structural and functional analyses. 
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INTRODUCTION 
Blood clotting is a series of sequential proteolytic events in which zymogens of serine 
proteases are converted into active enzymes, ultimately causing fibrin clot formation and platelet 
activation (1,2).  These coagulation enzymes belong to the chymotrypsin family (with trypsin-
like substrate preference) and share extensive structural homology between their catalytic 
domains (3-5).  However, unlike certain subsets of the protease family, such as the serine 
proteases of digestion, which show a low degree of specificity for substrates (6), the coagulation 
proteases select their cognate protein substrates with remarkable and distinctive specificity (7).  
Macromolecular substrate recognition and serine protease specificity are critical to tightly 
regulate hemostatic response.   
One determinant of coagulation protease specificity is clearly related to the active site-
dependent recognition of the substrate.  The catalytic clefts of the coagulation proteases favor P1 
Arg residues and also certain sequences surrounding the cleavage sites in their cognate zymogen 
substrates (8-11).  
Yet another prevailing hypothesis is that extended substrate interaction sites within 
enzyme complexes (exosites) play significant roles in regulating macromolecular substrate 
recognition and enzyme specificity.  The mechanism of exosite-dependent substrate recognition 
is exemplified by the case of the prothrombinase complex in coagulation, in which factor Va 
(FVa) is proposed to provide exosites to bind the substrate, prothrombin, in complex with its 
cognate protease factor Xa (FXa) (7,12,13).  Such a mechanism could be involved in other 
reactions catalyzed by cofactor-dependent coagulation proteases on their protein substrates in the 
clotting cascade. 
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Tissue factor (TF) is the cofactor for the serine protease, factor VIIa (FVIIa), which 
initiates the blood clotting (14,15).  A series of mutagenesis studies have suggested the presence 
of an extended substrate-binding site on TF that assists FVIIa in recognizing its protein 
substrates, factors IX (FIX) and X (FX) (16-21).  Initial studies have shown that alanine 
mutagenesis and chemical modification of Lys165 and Lys166 on TF substantially reduce the 
rate of FX activation by TF/FVIIa, but lack effect on the affinity of FVIIa for TF (16-18).  These 
results suggest that Lys165 and Lys166 on TF may form direct contacts with the γ-
carboxyglutamate-rich domain (Gla domain) of FX, presumably assisted by the membrane 
surface and/or the Gla domain of FVIIa.  Subsequent alanine-scanning mutagenesis studies have 
further identified regions on TF which appear to be important for macromolecular substrate 
recognition (19-21).  The studies of the antibody inhibition of TF and FVIIa (22-24), as well as 
the crystal structure of sTF/FVIIa (25,26), provide additional experimental evidence consistent 
with the postulation that exosite docking is critical to govern macromolecular substrate 
recognition by TF/FVIIa. 
Despite extensive study, the molecular basis for macromolecular substrate recognition by 
TF/FVIIa remains to be illuminated, i.e.; the extent of the exosite on TF, possible interaction 
site(s) on substrates, and the function of the exosite in the ternary enzyme/cofactor/substrate 
complex.  Moreover, the precise docking of the macromolecular substrates, FX and FIX, with 
TF/FVIIa has not been established, due to the difficulties of obtaining crystal structures of the 
ternary complex representing such weak and transient protein-protein interactions.  Thus, novel 
approaches would be useful to address these questions. 
In this study, we used yeast surface display followed by fluorescence-activated cell 
sorting (FACS) to select TF mutants in which the resulting TF/FVIIa complexes have enhanced 
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affinities for their major protein substrates, FIX and FX.  These gain-of-function mutants may 
result in stable TF/FVIIa/FIX or TF/FVIIa/FX complexes which would permit a variety of 
structural and functional analyses. 
 
EXPERIMENTAL PROCEDURES 
Materials 
Materials were from the following suppliers: porcine brain phosphatidylserine (PS) and 
egg phosphatidylcholine (PC), Avanti Polar Lipids (Alabaster, AL); recombinant human FVIIa, 
Spectrozyme FVIIa and Spectrozyme FXa, American Diagnostica (Greenwich, CT); human 
plasma FIX and FX, Enzyme Research Laboratories (South Bend, IN); Alexa Fluor® 647 
protein labeling kit and streptavidin-phycoerythrin (SA-PE), Invitrogen (Carlsbad, CA); and 
fluorescein-Phe-Pro-Arg-chloromethylketone (fl-FPRck), Haematologic Technologies, Inc. 
(Essex Junction, VT).  Fl-FVIIa was prepared by reacting FVIIa to completion with fl-FPRck 
(confirmed by loss of enzymatic activity), after which excess inhibitor was removed by dialysis.  
Alexa-HPC4 was prepared by labeling HPC4 monoclonal antibody with Alexa Fluor 647 through 
a slight modification of the method provided by the manufacturer. 
 
Yeast surface display 
The first round of library sorting 
A random cDNA library of mutations in the TF ectodomain (termed soluble TF, or sTF) 
was prepared essentially as described (27,28).  Briefly, random nucleotide errors were 
incorporated into the sTF coding sequence using Taq polymerase (Invitrogen, Carlsbad, CA) 
with 0.5 mM MnCl2 and 2 mM MgCl2 to achieve a 0.3% error rate, and then cloned into the 
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pCT302 yeast display vector by homologous recombination.  Transformed EBY100 yeast were 
grown in SD-CAA medium (2% dextrose, 0.67% yeast nitrogen base, 1% casamino acids) at 
30°C for 48 h; sTF expression was then induced in SG-CAA medium (2% galactose, 0.67% 
yeast nitrogen base, 1% casamino acids) at 20°C for 18-20 h (27,29).  A high level of expression 
of sTF was verified on the yeast surface by flow cytometry using the Alexa-HPC4 (a 
fluorescently-labeled antibody to the HPC4 epitope tag at the N-terminus of sTF).  TF-
expressing yeast cells were first incubated with a saturating level of fl-FVIIa (30 nM) for 15 min, 
after which biotinylated FX (0.5 μM) was added for an additional 20 min.  After being washed 
briefly with ice-cold HBSAC (25 mM HEPES pH 7.4, 100 mM NaCl, 5 mM CaCl2, 0.5% BSA, 
0.1% NaN3), the cells were then incubated with SA-PE for 30 min at 4°C to form PE-SA-
biotinylated FX tetravalent complexes, washed again, followed by sorting in purification mode 
using a Cytomation MoFlo sorter (DakoCytomation, Ft. Collins, CO) with an event rate of 
~50,000 cells/s (27,30).  A total of 6×107 cells were examined during the first selection, from 
which the top ~0.5% of the population with the highest PE-SA-biotinylated FX binding signal 
still retaining full fl-FVIIa binding was collected and cultured at 30°C in SD-CAA, followed by 
induction at 20°C in SG-CAA to induce protein expression.  After four additional selections with 
biotinylated FX in the presence of fl-FVIIa and growth, the sorted cells were plated on SD-CAA 
plates (SD-CAA containing 1 M sorbitol) to isolate individual clones.  Plasmids were rescued 
from isolated yeast clones using a Zymoprep miniprep kit (Zymo Research, Orange, CA) and 
subjected to DNA sequencing.  
Representative sTF mutants containing certain mutations from the selection were cloned 
in E. coli, expressed and purified as described (31).  The properties of these sTF mutants to 
support FX activation were examined further. 
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The second round of library sorting 
For the second round, sTF mutants G87D and E216K were chosen as the starting point.  
An additional round of mutagenesis and multiple selections were carried out for two libraries 
generated from sTF mutants G87D and E216K respectively, by a modification of the method of 
the first round of library sorting described above.  Using cDNAs of mutated sTF (G87D or 
E216K) as the templates, two random mutant libraries of sTF cDNAs were prepared by error-
prone PCR.  These were denominated lib-G87D and lib-E216K, respectively.  A total of 1.2×108 
cells were examined per each library during the first selection.  After incubating with 80 nM fl-
FVIIa and 0.4 μM biotinylated FX, followed by SA-PE, the top ~0.5% of the population with the 
highest PE-SA-biotinylated FX binding signal still retaining full fl-FVIIa binding was collected 
and cultured in SD-CAA, followed by induction in SG-CAA.  After four additional selections 
with PE-SA-biotinylated FX in the presence of fl-FVIIa, the sorted cells were plated on SD-CAA 
plates to isolate individual clones.  Plasmids were rescued from isolated yeast clones using a 
Zymoprep miniprep kit, and subjected to DNA sequencing.  
Representative sTF mutants from the selection were cloned in E. coli, expressed and 
purified as described (31).  The properties of these sTF mutants to bind to FVIIa and support FX 
activation were examined in further detail.  
 
Characterization of the substrate binding properties of sTF mutants 
Representative sTF mutants from the library sorting were each transformed in EBY100 
yeast, after which yeast cells were cultured in SD-CAA medium at 30°C for 48 h and then 
induced in SG-CAA medium at 20°C for 18-20 h (27-29).  A high level of expression of sTF was 
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confirmed by incubating the yeast cells with Alexa-HPC4, as described above.  In each sample 
tube, 1×106 TF-expressing yeast cells were first incubated with a saturating level of fl-FVIIa (65 
nM) for 15 min, after which biotinylated FX at various concentrations was added and incubated 
for an additional 20 min.  After being washed briefly with ice-cold HBSAC, yeast cells were 
then incubated with SA-PE for 30 min at 4°C, washed again, and sorted using a BD FACSCanto 
cytometer (BD Biosciences, San Jose, CA) with an event rate of ~10,000 cells/s.  Since the 
fluorescence intensity of fl-FVIIa indicated the sTF expression level of each sample, the relative 
mean fluorescence units (MFU) value was calculated from the mean fluorescence intensity of 
PE-SA-biotinylated FX normalized to that of fl-FVIIa.  The quadratic ligand binding equation 
was fitted to plots of the relative MFU versus [biotinylated FX] to derive the apparent 
association constant Kd values of FX binding to sTF-displayed yeast cells.  Additionally, the 
same experiments were performed using biotinylated FIX instead of biotinylated FX to estimate 
the apparent Kd values for FIX binding to sTF mutants on yeast surface in the presence of FVIIa. 
 
FVIIa binding 
Binding affinities of FVIIa for sTF in solution were quantified using the TF-dependent 
amidolytic activity of FVIIa as the readout for complex formation.  Briefly, increasing 
concentrations of sTF were incubated with FVIIa (4 nM) for 5 min in HBSAC buffer, after 
which Spectrozyme FVIIa was added to a final concentration of 1 mM.  The rate of hydrolysis of 
Spectrozyme FVIIa by sTF/FVIIa was measured in A405.  The quadratic ligand binding equation 
was fitted to the amidolytic activity data to derive the apparent Kd values for the binding of 
FVIIa to sTF (32). 
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FX activation 
Activation of FX by TF/FVIIa in solution was quantified via two-stage discontinuous 
chromogenic assays as described (33), with the following modifications:  FVIIa and sTF variants 
were first incubated for 5 min in HBSAC buffer, after which FX was added.  Reactant 
concentrations were: 10 nM FVIIa, 100 nM sTF, and varying concentrations of FX.  Timed 5 µl 
aliquots were removed over a 10 min period, and quenched in 25 µl Stop Buffer (60 mM Mes-
NaOH pH 5.8, 75 mM EDTA, 50 mM NaCl, 8% Lubrol PX).  FXa concentrations were 
quantified by adding 10 µl HBSAC buffer, 10 µl 2.0 M Tricine-NaOH (pH 8.4), and 50 µl 1 mM 
Spectrozyme FXa (chromogenic substrate), then the increase in A405 was measured.  Amounts of 
FXa generation were determined from a standard curve established with purified FXa. 
 
RESULTS AND DISCUSSION 
The first round of library sorting 
Yeast surface display technique was used as a platform for expressing a random library of 
mutant sTF cDNAs.  The expression of sTF was verified on yeast surface by flow cytometry 
using the Alexa-HPC4.  Once sTF expression had been confirmed, TF-expressing cells with 
enhanced binding affinity to FX were further enriched using flow cytometry.  Briefly, TF-
expressing yeast cells were first incubated with a saturating level of fl-FVIIa and a low 
concentration of PE-SA-biotinylated FX complex, washed again, and followed by flow 
cytometry sorting.  Fig. 9 depicted such a two-color labeling scheme, consisting of one 
fluorophore (fluorescein) for sTF expression and another (PE) for FX binding.  Fl-FVIIa was 
used in cell labeling, not only to ensure the optimal binding between sTF and FX, but also to 
indicate the sTF expression level on yeast surface.  Yeast colonies of interest were ones with the 
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highest FX binding signal in the double-positive quadrant (the sort gate in Fig. 10C and D).  The 
flow cytometry control data showed an unlabeled yeast population (Fig. 10A) and a population 
labeled with fl-FVIIa (Fig. 10B).  In every flow cytometry yeast display experiment, there were 
always two distinct populations (Fig. 10B-F).  The lower negative peak represented the 
population of yeast cells which cannot bind to FVIIa.  These yeast cells may not express sTF on 
their surface due to plasmid loss.  Another explanation is that even when expressed on the yeast 
surface, some sTF variants will lose FVIIa binding affinity upon mutation.  The negative 
population was around 90% of the total cell population in the initial sorting (Fig. 10C and E), but 
was diminished to as few as 20% in successive selections.  This was probably due to the 
elimination of sTF variants that had lost their binding abilities to fl-FVIIa (Fig. 10D and F).  A 
total of 6×107 cells were examined during the first selection.  In the early selection, the FX 
binding signal varied with each yeast colony; still it was difficult to observe a PE signal in the 
double-positive quadrant, as sTF mutants with enhanced affinities to FX may be rare in the total 
population (Fig. 10C and G).  The top 0.05~0.5% population with the most enhanced FX binding 
signal, but still retaining normal fl-FVIIa binding, was collected and cultured again, followed by 
another selection.  After three flow cytometry selections, a double-positive population began to 
appear.  By the fifth selection, a significant enrichment in the FX-positive population was 
observed (Fig. 10D and H), after which twenty-five colonies from the most fluorescent cells 
were chosen and their sTF cDNAs sequenced.  This resulted in twenty-three sTF cDNA 
sequences (Table 2).  The result from the first round of library sorting was a collection of sTF 
mutants that fell into five groups with multiple identical mutations in each group: seven clones in 
group A; three in group B, C, and D; two in group E, and five mutants that did not fall into a 
group.  Many of the mutations introduced charged residues on the surface of sTF, which might 
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create novel interactions with residues in substrates and/or FVIIa.  For example, several 
mutations (M210V, Q212R, G215R, E216D/K) lay at the C-terminal tail of sTF which connects 
the ectodomain and transmembrane domain of TF, and therefore should be adjacent to the Gla 
domains of substrates and/or FVIIa.  In published sTF crystal structures, this linker region lacked 
interpretable electron density (25,34).  Its flexibility, therefore, should permit interactions with 
the Gla domains of substrates and/or FVIIa.  Mutated residues G81R, G87D, and S88A were 
either in, or near, a flexible surface loop of TF, from Asn83 to Gly90, which has no electron 
density in most sTF crystal structures (25,34).  This loop is thought to be located at a height on 
the membrane surface that might permit direct contacts with the EGF2 domain of FVIIa.   
Among the mutations in each clone, some (one or possibly two) may have a critical role 
in increasing FX binding, while others may have occurred randomly or incidentally.  There was a 
common mutation (Glu216) that was repeatedly found in groups A, B and C.  Such common 
mutations appearing in different groups should have an increased probability of being mutations 
that actually contribute functionally.  Taking this into consideration, we next examined, in detail, 
the abilities of sTF mutants to support FX activation, in order to find out which mutations were 
responsible for the enhanced FX binding signal in the first round of library sorting.  
 
FVIIa-dependent activation of FX by sTF mutations 
A stringent test of TF/FVIIa complex function is its ability to support the activation of its 
natural protein substrate, FX.  We therefore compared the abilities of both wild-type and various 
sTF mutants to support the activation of FX under equivalent concentrations of enzyme (10 nM 
FVIIa) and cofactor (100 nM TF).  The kinetic constants for FX activation by sTF/FVIIa in 
solution are summarized in Table 3.  The tested sTF variants included representative sTF 
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mutants of group A, B, C and D.  Group A and B had significantly reduced Km values and 
comparable kcat values with respect to the sTF wild-type values, indicating a productively 
increased FX binding.  That is, with these sTF mutants, FX binds with higher affinity to 
TF/FVIIa in such a way that it can still be activated to FXa with essentially wild-type Km.  Group 
C showed a moderately reduced Km value relative to wild type, while group D retained 
essentially wild-type Km value.  Furthermore, sTF variants were generated with single or 
multiple mutations observed in each group (e.g., E128D from group A).  The abilities of sTF 
variants to support FX activation by FVIIa in solution were examined (also listed in Table 3).  
Two variants were generated based on mutations in group A: one with a single mutation at 
E128D; another with several adjacent mutation sites at M210V, Q212R and E216D.  The former 
one had comparable Km and kcat values relative to wild type; while the latter one had increased 
Km and kcat values.  Group B had reduced Km value relative to wild type, but not by the single 
mutation G81R.  Thus, sTF mutant E216K, which had reduced Km value, was more likely 
responsible for the reduced Km value of group B.  For group C, two mutants were generated; sTF 
mutant G87D with a reduced Km value; and sTF mutant having two mutation sites G215R and 
E216K with a slightly higher Km value relative to wild type.  Even though group D retained wild-
type Km value, single mutation E183G had a reduced Km value.  Together, two sTF mutations 
G87D and E216K were deemed to have the best potential in enhancing FX binding affinity, 
according to their observed abilities to support FX activation. 
 
The second round of library sorting 
The library size of yeast surface display screening is such that one is likely to obtain only 
a single favorable amino acid change per clone; however, it typical requires two or three 
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mutations per clone in order to achieve the desired properties of the resulting protein, such as an 
enhanced affinity of the mutated protein to the target ligand (35).  This necessitates multiple 
iterations of mutagenesis and selection.  Accordingly, in order to fully enhance the affinity of 
sTF for FX, the sTF mutants G87D and E216K were chosen as the starting point, and another 
round of library sorting was carried out for two libraries based on G87D and E216K respectively 
(Fig. 11).  By the fifth selection, the mean fluorescence of yeast cells’ binding for PE-SA-
biotinylated FX was substantially increased for both libraries (Fig. 11C, D, K, and L).  Finally, 
the most fluorescent colonies were chosen for each library and sequenced for the sTF cDNA 
inserts, from which eighteen clones were obtained for the lib-G87D, and sixteen for the lib-
E216K (Table 4).  The result of the second round of library sorting was a collection of TF 
mutants that fell into several groups, but with multiple identical mutations in each group.  For the 
lib-G87D, fourteen clones were in group I, and three in group II.  One clone (iii) did not fall into 
a group.  Besides G87D, groups I and II had two additional mutations in common: residues 
Q190R and D204G.  The only difference between clone iii compared to group II was the lack of 
mutation F147Y.  For the lib-E216K, there were six clones in group IV, two in group V and 
eight mutants that did not fall into a group.  There were common mutation sites repeatedly 
presenting in different groups and clones: N137S/D/G in clones x, xi, xii, and xiii; E183G in 
group IV, as well as clones vi, vii, and xiii; S195F/P in groups IV and V, as well as clones vi and 
vii; D204N/Y/G in group V, and clones ix, x, xi, and xiii.  Thus, mutations Q190R and D204G 
were obtained from all groups in the lib-G87D, as well as multiple groups and clones in the lib-
E216K.  Interestingly, E183G was one of the mutations selected by the first round of library 
sorting which appears to have reduced Km value relative to wild type in FX activation; it was 
obtained again independently from the second round of sorting.  
57 
 
Among the mutations obtained from the second generation of yeast surface display 
sorting, the effects of TF mutations N137 and D204 on FVIIa-dependent substrate activation 
have previously been tested by Kirchhofer et al. (20), in which the activities of sTF mutants in 
FX and FIX activation assays performed in the presence of SW-13 cell membranes were 
compared with those of wild-type sTF.  The sTF mutant N137A supported rates of FX and FIX 
activation that were both >75% of wild type, and the sTF mutant D204A supported rates that 
were 30-75% and > 75% of wild type respectively.  Previous study from our lab reported that TF 
mutant E183A had >70% activity relative to wild type in FVIIa-dependent FX activation using 
membrane TF-liposomes with 5% PS/95% PC.  Therefore, the previous studies have suggested 
that those mutations mentioned above have no effect on the physiological function of TF as a 
cofactor to FVIIa activity, with caveats, however, about interpretation owing to the vastly 
different membrane and protein conditions used in those studies relative to the present study.   
 
Characterization of sTF mutants by titration 
To our knowledge, the binding properties of different antibodies to antigens on yeast cell 
surface were in quantitative agreement with those measured in solution or by biosensor methods 
(28).  Hence, the binding affinity of sTF variants for biotinylated FX was conveniently “titrated” 
while displayed on the surface of the yeast.  Yeast cells were double-labeled with fl-FVIIa plus 
biotinylated FX at various concentrations, followed by SA-PE.  The MFU values were calculated 
from the fluorescence histograms for the gated positive population of fl-FVIIa binding in flow 
cytometry analyses.  Fig. 12 showed a representative fit of the relative MFU values of PE versus 
substrate concentrations.  The apparent association constant, Kd, of biotinylated FX binding to 
sTF mutants displayed on yeast cells are reported in Table 5, and ranged from 100 to 850 nM.  In 
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contrast, binding of biotinylated FX to wild-type sTF on the yeast surface was too weak to 
estimate its Kd.  Even though the substrate, FX, was targeted in the library sorting, in 
consideration of the fact that substrates FIX and FX have been proposed to interact with the same 
TF region (20), we speculate that these sTF mutants might have reduced Kd values for FIX 
binding as for FX.  As expected, representative clones from groups I, II and IV showed lower 
apparent Kd values for biotinylated FIX binding which ranged from 0.3 to 0.8 μM. By 
comparison, the apparent Kd value of wild-type sTF was about 2.5 μM.  Interestingly, by 
comparing the apparent Kd values for different sTF variants, group I had the lowest apparent Kd 
value for biotinylated FIX, while group IV had the lowest one for biotinylated FX.  Thus, this 
finding suggests that these sTF mutants may have different preferences for binding toward 
different substrates. 
 
Amidolytic acitivity and FVIIa binding  
Subsequently, the representative sTF mutant of group IV was cloned in E. coli, 
expressed, and purified as described (31).  The ability of the representative sTF mutant to bind 
FVIIa was examined in the FVIIa chromogenic assays.  As shown in Table 6, the representative 
sTF mutant exhibited the wild-type level of cofactor function toward the amidolytic activity of 
FVIIa.  FVIIa binding to wild-type sTF had the apparent association constant Kd value of 1.1 ± 
0.1 nM.  The binding affinity of FVIIa to the representative sTF mutant of group IV was 
essentially the same as wild type, with very similar Kd (0.95 ± 0.02 nM).   
 
FVIIa-dependent activation of FX by sTF mutations 
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We then tested the ability of the representative sTF mutant of group IV to support the 
activation of FX by FVIIa in solution (Table 6).  Both the kcat and the Km values for the 
representative sTF mutant were actually similar to wild-tpye sTF, leading to a slightly higher 
overall catalytic efficiency (kcat / Km). 
Importantly, the gain-of-function sTF mutations selected from library sorting with 
enhanced FX binding are all located outside the putative sTF exosite region, suggesting that the 
interactions between the sTF exosite and FX are likely to be preserved.  Consistent with this 
deduction, these sTF mutants showed comparable Km and kcat values relative to wild-type sTF in 
FX activation assays, meaning that the putative substrate-binding region probably maintained the 
same status as in wild type without interruption.  We speculate that these mutations probably 
create new, ectopic interactions (such as new salt bridges) between sTF and FX and/or FVIIa in 
order to stabilize TF/FVIIa/FIX or TF/FVIIa/FX complexes.   The formation of such stable 
ternary complexes permits multiple ways to investigate the interactions within the cofactor-
protease-substrate complex, which are otherwise too transient to study.  One ideal use of TF 
mutants with enhanced affinity for FX might be using various NMR approaches to obtain highly 
detailed structural information about any conformational changes in TF when it binds to FVIIa, 
and then, FX.  Moreover, if x-ray crystal structures of the ternary complex can be obtained using 
these TF mutants, this may constitute a means of studying not just the putative exosite on TF, but 
also all kinds of interactions within the ternary complex. 
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TABLES AND FIGURES 
TABLE 2. Results from the first round of library sorting for sTF variants with enhanced affinity for 
FX. 
Group No.# of identical clones Mutations 
A 7 E128D, M210V, Q212R, E216D 
B 3 G81R, E216K 
C 3 G87D, G215R, E216K 
D 3 T121A, E183G 
E 2 S88A, G164R 
F 1 D66N, N124K 
G 1 D204N 
H 1 D204G 
I 1 N82D, E95G, T167K 
J 1 Q190R 
 
 
 
TABLE 3. Kinetic constants for FX activation by FVIIa in complex with representative sTF 
variants from the first round of library sorting. 
Reaction mixtures consisted of 10 nM FVIIa, 100 nM sTF, and varying concentrations of FX, in 
the absent of any phospholipid membrane.   
Group Mutation Km (nM) kcat (min-1) kcat / Km (M-1 s-1)
 wild type 2.7 ± 0.2 1.1 ± 0.04 6.8 × 103 
A E128D, M210V, Q212R, E216D 1.6 ± 0.2 1.2 ± 0.2 12.5 × 103 
 E128D 2.8 ± 0.3 0.86 ± 0.03 5.1 × 103 
 M210V, Q212R, E216D 14 ± 5.7 9.0 ± 1.7 10.7 × 103 
B G81R, E216K 1.8 ± 0.5 0.76 ± 0.07 7.0 × 103 
 G81R 2.3 ± 0.6 0.65 ± 0.06 4.7 × 103 
 E216K 1.4 ± 0.2 1.7 ± 0.4 20.2 × 103 
C G87D, G215R, E216K 2.3 ± 0.5 0.97 ± 0.2 7.0 × 103 
 G87D 1.4 ± 0.2 0.67 ± 0.04 8.0 × 103 
 G215R, E216K 3.0 ± 0.1 1.4 ± 0.1 7.7 × 103 
D T121A, E183G 2.5 ± 0.1 0.83 ± 0.1 5.5 × 103 
 T121A 2.5 ± 0.1 0.82 ± 0.1 5.5 × 103 
 E183G 1.0 ± 0.1 0.84 ± 0.2 14.0 × 103 
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TABLE 4. Results from the second round of library sorting for sTF variants with enhanced affinity 
for FX. 
 Group No.# of identical clones Mutations 
 
lib-
G87D 
I 14 G87D, G164R, Q190R, D204G 
II 3 K28R, G87D, F147Y, Q190R, D204G 
iii 1 K28R, G87D, Q190R, D204G 
 
 
 
 
lib-
E216K 
IV 6 E183G, S195F, E216K 
V 2 T139I, S195P, D204N, Q212R, E216K 
vi 1 T6P, E183G, S195F, E216K 
vii 1 E183G, S195F, E216K, T139I, I152T, K165R, K181R, Q212R
viii 1 Q190R, E216K 
ix 1 Q190R, D204Y, S205G , E216K 
x 1 N137S, D204N, S205G, E216K 
xi 1 N137D, S202G,D204N, E216K 
xii 1 N137D, E216K 
xiii 1 N137G, E183G, S202G, T203A, D204G, E216K 
 
 
 
TABLE 5. Apparent dissociation constants of biotinylated substrates to yeast-displayed sTF 
variants. 
  Biotinylated FX Biotinylated FIX 
Group Mutation apparent Kd (μM) apparent Kd (μM) 
wild type wild type N.D. a 2.4 ± 0.11 
I G87D, G164R, Q190R, D204G 0.69 ± 0.05 0.30 ± 0.05 
II K28R, G87D, F147Y, Q190R, D204G 0.85 ± 0.14 0.75 ± 0.13 
IV E183G, S195F, E216K 0.11 ± 0.02 0.64 ± 0.12 
 
aBinding of biotinylated FX to yeast expressing wild-type sTF was not detectable. 
  
 
TABLE 6. Binding and kinetic constants for the representative sTF variant of group IV in complex 
with FVIIa. 
 
Reaction mixtures did not contain any phospholipid membrane.   
   FVIIa binding  FX activation 
Group Mutation  apparent Kd (nM)  Km (nM) kcat (min-1) kcat / Km (M-1 s-1)
wild type wild type  1.1 ± 0.1 2.7 ± 0.2 1.1 ± 0.04 6.8 × 103 
IV E183G, S195F, E216K  0.95 ± 0.02  2.6 1.2 7.7 × 103 
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FIGURE 9. Cartoon depictions of the yeast surface display system using a two-color labeling scheme 
for flow cytometry sorting. The TF ectodomain (blue) was expressed as an Aga (purple) fusion protein 
on the surface of yeast. During the flow cytometry sorting, expression of sTF could be detected by using 
fl-FVIIa (burgundy), and binding of sTF to the biotinylated FX (green) could be detected using PE-avidin 
(orange). Only yeast cells that bound the highest level of biotinylated FX while retaining fl-FVIIa binding 
ability were selected.  
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FIGURE 10. Flow cytometry data of the first round of library sorting. A, unlabeled yeast cells. B, 
yeast cells labeled with fl-FVIIa, compensated to reject crosstalk between the fluorescein and 
phycoerythrin channels. Yeast cells in the initial (C) and final (D) selection of flow cytometry sorting. 
Cells were double-labeled with fl-FVIIa as in B, plus biotinylated FX followed by SA-PE. The green 
outline indicates the fl-FVIIa positive population, while the yellow outline indicates a typical sort gate. 
Histogram of PE signal for cells in the initial (E) and final (F) selection of flow cytometry sorting. The 
mean fluorescence of yeast cells binding for PE-SA-biotinylated FX was substantially increased relative 
to the initial selection in the final selection. Histogram of fl-FVIIa signal for cells in the initial (G) and 
final (H) selection of flow cytometry sorting, indicating yeast surface expression of sTF. The left peak 
represents the fraction of yeast which loses fl-FVIIa binding ability. The green gate of the right peak 
indicates the fl-FVIIa positive population.  
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FIGURE 11. Flow cytometry data of the second round of library sorting. Yeast cells in the initial (A, 
lib-G87D; C, lib-E216K) and final (B, lib-G87D; D, lib-E216K) selection of flow cytometry sorting. 
Cells were double-labeled with fl-FVIIa plus biotinylated FX followed by SA-PE. The green outline 
indicates the fl-FVIIa positive population, while the yellow outline indicates a typical sort gate. Histogram 
of fl-FVIIa signal for cells in the initial (E, lib-G87D; G, lib-E216K) and final (F, lib-G87D; H, lib-
E216K) selection of flow cytometry sorting, indicating yeast surface expression of sTF. The green gate of 
the right peak indicates the fl-FVIIa positive population. Histogram of PE signal for cells in the initial (I, 
lib-G87D; K, lib-E216K) and final (J, lib-G87D; L, lib-E216K) selection of flow cytometry sorting. 
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FIGURE 12. Direct binding of biotinylated FX to yeast-displayed sTF variants. TF-expressing yeast 
cells (wild type sTF ; the representative clone of group IV ) were first incubated with saturating levels 
of fl-FVIIa (65 nM) for 15 min, after which biotinylated FX at various concentrations was added, and 
incubated for additional 20 min. After being washed briefly with HBSAC, yeast cells were then incubated 
with SA-PE for 30 min, washed again, and followed by flow cytometry. The relative MFU values were 
calculated as described in Experimental Procedures. The apparent Kd value was the mean ± standard error 
of three independent fits of the relative MFU value versus substrate concentration. 
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CHAPTER 4: THE ACTIVATION OF FACTOR VII BY A VARIETY OF  
POTENTIAL ACTIVATORS 
ABSTRACT 
Factor VII (FVII) is an inactive zymogen, which upon proteolysis of a single peptide 
bond, is activated to the serine protease factor VIIa (FVIIa).  In this study, the activation of FVII 
was evaluated under identical conditions by potential in vivo activators, including factor Xa 
(FXa), factor IXa (FIXa), α-thrombin, meizothrombin, factor XIIa (FXIIa), factor XIa (FXIa), 
and FVIIa in complex with tissue factor (TF).  In order to avoid the influence of FVII 
autoactivation to the analyses of FVII activation by other activators, a FVII mutant (S344A) was 
generated, in which the active site serine residue has been mutated to alanine.  Experiments were 
performed on phospholipid vesicles, in the presence of either relipidated membrane-anchored TF 
or soluble TF (or no TF).  The initial activation rates of FVII were determined using the FVII 
activation assays, followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis and 
Western blotting techniques.  The rates of FVII activation on membrane-anchored TF in 
liposomes by FXa, FIXa, meizothrombin, and α-thrombin were 69.5, 3.2, 20.7×10-4, and 2.5×10-
5 nM/min/nM enzyme, respectively, which indicated that FXa and FIXa were the most potent 
activators of FVII.  FVII autoactivation by TF/FVIIa was evaluated, yielding a two-dimensional 
second-order rate constant of 1.0×107 m2/mol/s.  TF facilitated the rate of FVII activation by 3 to 
9-fold, depending on the activators.  Factor Va (FVa), the cofactor for FXa in thrombin 
generation, did not influence the activation of FVII by FXa.  This study sheds light on how FVII 
is activated in physiological conditions. 
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INTRODUCTION 
Factor VII (FVII) is a 50,000 Da trypsin-like serine protease that is synthesized in the 
liver, and then circulates in plasma as a zymogen (1,2).  The plasma concentration of FVII is 10 
nM (500 ng/ml), in which roughly 1% of FVII circulates in the active form factor VIIa (FVIIa) 
(3,4).  Zymogen FVII is a single polypeptide chain of 406 amino acids, converted to FVIIa by 
limited proteolysis at a single peptide bond (Arg152–Ile153).  It has been reported that, in vitro, 
FVII can be activated to FVIIa by many proteases, including factor Xa (FXa) (5-7); factor IXa 
(FIXa) (6-8); thrombin (5,7); and factor XIIa (FXIIa) (8,9); as well as FVIIa in complex with 
tissue factor (TF) (7,10).  It is presently unclear which of these proteases plays the major role in 
activating FVII during clotting, although FXa is generally considered as the most likely 
candidate.  Also, the influence of TF on FVII activation by various activators has been 
controversial.  In the studies mentioned above, the experimental conditions varied from 
publication to publication.  Additionally, some previous studies utilized FVIIa generation assays 
that followed the amidolytic activity of newly-generated FVIIa.  However, under those 
experimental conditions, it was unclear if FVII autoactivation by FVIIa in the presence of TF 
would contribute to the analyses of FVII activation by other activators. 
An unusual kinetic mechanism is involved in the autoactivation of FVII regarding 
substrate presentation: the enzyme, FVIIa, is bound to one TF molecule, while the substrate, 
FVII, is bound to a separate TF molecule  (10).  The TF/FVIIa and TF/FVII complexes must 
therefore diffuse laterally in the plane of the membrane to encounter each other.  Consequently, 
the reaction rates are governed by the surface density of TF/FVII(a) complexes on the 
membrane, rather than the molar concentrations of any of the reactants.  The autoactivation of 
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FVII might be important in initiating the clotting cascade, yet its precise role needs further 
elucidation. 
As mentioned above, approximately 1% of FVII circulates in plasma as activated FVIIa, 
with a half-life of about two hours (3).  These low initial levels of FVIIa are thought to trigger 
the clotting cascade upon exposure to TF, causing the back-activation of the rest of the zymogen 
FVII by downstream proteases.  One question that remains to be solved is where and how the 
basal levels of FVIIa in circulation are generated.  Findings from several studies suggest that the 
formation of the circulating FVIIa found in plasma may occur on lipoprotein particles, 
apparently involving FIX (presumably as FIXa) (11,12).   
In the present study, the activation of FVII by potential in vivo activators was evaluated 
under identical conditions, both in the absence and presence of cofactors.  In order to avoid the 
confounding influence of FVII autoactivation to the analyses of FVII activation by other 
activators, a FVII mutant (S344A) was generated, in which the active site serine residue has been 
mutated to alanine.  This study is designed to shed light on several unresolved questions 
regarding FVII activation: 1) which protease plays major role in activating FVII during clotting?; 
2) what are the influences of various protein cofactors on FVII activation?; and 3) where and 
how are the basal levels of the circulating FVIIa generated? 
 
EXPERIMENTAL PROCEDURES 
Materials 
Materials were from the following suppliers: porcine brain phosphatidylserine (PS), liver 
phosphatidylethanolamine (PE) and egg phosphatidylcholine (PC), Avanti Polar Lipids 
(Alabaster, AL); transformed human embryonic kidney cells (HEK293), ATCC (CRL-11268) 
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(Manassas, VA); Opti-MEM reduced serum medium, Invitrogen (Grand Island, NY); and G418 
sulfate, Cellgro (Manassas, VA). 
 
Proteins 
Recombinant human FVIIa was purchased from American Diagnostica (Greenwich, CT).  
Human plasma FIXa, FXa, and α-thrombin were purchased from Enzyme Research Laboratories 
(South Bend, IN).  Human factor Va (FVa) was purchased from Haematologic Technologies, 
Inc. (Essex Junction, VT).  Meizothrombin was a generous gift from Dr. Ingrid Verhamme 
(Vanderbilt University, Nashville, TN). 
Membrane-anchored TF (membTF) and soluble TF (sTF) were expressed in E. coli, and 
purified as described (13,14).  Additionally, purified membTF was incorporated into liposomes 
as described previously (15), using Bio-Beads® SM-2 and 44 mM n-octyl-β-D-glucopyranoside.  
The molar ratios of membTF to total phospholipid varied from about 1:1000 to 1:3000 for FVII 
activation by TF/FVIIa; and were about 1:1000 for the rest of the activators.  The concentrations 
of available TF on the outside of the liposomes were quantified by titration with FVIIa as 
described previously (16).  Concentrations of membTF in liposomes are reported here as the 
available TF concentrations.  
The FVII S344A mutation was prepared by the polymerase chain reaction mutagenesis 
methods using wild-type FVII cDNA as the template as described previously (17), and then 
shuttled into the pcDNA3.1 (+) vector.  Stably cell lines expressing the mutant FVII were 
prepared by transfection of HEK293 cells, as described earlier (18).  Cells were grown in Opti-
MEM medium with 10% fetal bovine serum for 48 h, and then switched to the same medium 
supplemented with 400 μg/ml of G418.  Expression of FVII in the medium was determined by 
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ELISA.  Cell lines exhibiting maximal expression of FVII protein were expended in T-175 cm2 
flasks (Corning Life Seciences, Corning, NY).  Upon reaching confluence, cells were rinsed 
three times with PBS, and then incubated in Opti-MEM reduced serum medium containing 10 
μg/ml vitamin K and 400 μg/ml G418.  The conditioned medium was harvested every 24 h for 
14 days, centrifuged to remove cellular debris, and then kept frozen until ready to be purified.  
Recombinant FVII (S344A) was purified from the conditioned media using a FVII affinity 
column followed by a Mono-Q HR 5/5 column (Amersham Pharmacia).  The fully γ-
carboxylated protein of FVII (S344A) was eluted form the Mono Q column at ~ 0.3 M NaCl.   
 
The time course of FVII activation by Western blotting 
FVII activation experiments, unless noted otherwise, were performed at 37°C in HBSPC 
buffer (25 mM Hepes, PH 7.4, 100 mM NaCl, 5 mM CaCl2, 0.1% PEG 8000, and 0.02% NaN3).  
Reaction mixtures consisted of 10 nM FVII (S344A), varying concentrations of activators, 50 
μM 20% PS/40% PE/40% PC phospholipids, in the presence of either 25 nM relipidated 
membTF, or 100 nM sTF, or no TF, shown in Table 7.  FVII autoactivation by the TF/FVIIa 
complex obeys a two-dimensional enzyme kinetic mechanism (10). Reaction mixtures consisted 
of 10 nM FVII (S344A), 0.5 nM FVIIa, and 15 nM relipidated membTF with varying TF surface 
densities on 20% PS/80% PC vesicles.  Timed 10 µl aliquots were removed over a 30 min 
period, and quenched in 6 µl SDS denaturing sample buffer (250 mM Tris-HCl, pH 6.8, 10% 
SDS, 30% Glycerol, 0.5M DTT, and 0.02% bromophenol blue), and then immediately incubated 
at 95°C for 5 min.  Samples were subjected to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), followed by overnight transfer to PVDF transfer membrane 
(Thermo Scientific, Rockford, IL).  Membranes were blocked in TBS containing 0.2% BSA and 
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0.05% Tween20 for 1 h, incubated with 0.45 μg/ml of polyclonal sheep anti-human FVII 
antibody (Haematologic Technologies, Essex Junction, VT) for 2 h, followed by incubation in a 
1:10000 dilution of peroxidase-conjugated bovine anti-goat IgG (Jackson ImmunoResearch 
Laboratories, West Grove, PA) for 1 h.  The washed membranes were immersed in Pierce ECL 
plus Western blotting substrate (Thermo Scientific, Rockford, IL) for 3 min, and exposed to 
Kodak BioMax Xar film (Eastman Kodak, Rochester, NY).  The intensities of the protein bands 
were quantified by densitometric analyses.  Amounts of FVIIa (S344A) generated were 
established by comparison to a standard curve determined with purified FVIIa (Fig. 13).  
 
FVII activation in the presence of FVa 
The activation of FVII by FXa in the presence of FVa was evaluated as described above, 
and compared with the experiments carried out in the absence of FVa.  FXa was added to 
HBSPC buffer containing 5 nM FVa, 10 nM FVII (S344A), 50 μM 20% PS/40% PE/40% PC 
phospholipids, in the presence of either 25 nM relipidated membTF, or 100 nM sTF, or no TF.   
 
RESULTS 
Initial rates of FVII (S344A) activation by various activators 
The initial rates of FVII activation by FXa, FIXa, meizothrombin, and α-thrombin were 
summarized in Table 8.  At the plasma concentration of FVII (10 nM), the initial activation rates 
of FVII (S344A) with membTF relipidated in liposomes by FXa, FIXa, meizothrombin, and α-
thrombin were 69.5, 3.2, 20.7 x 10-4, and 2.5 x 10-5 nM/min per nM enzyme (nM/min/nM) 
respectively.  Obviously, in terms of activation efficiency, FXa was found to be the most 
effective activator of FVII among the activators which have been tested in the present study.  
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These results are consistent with the speculation that FXa is most likely the predominant 
physiological FVII activator in the initial phase of blood clotting (7).  FIXa activated FVII at a 
30-fold slower rate than FXa under identical experimental conditions, but still with an 
appreciable activity.  α-thrombin had an initial rate of FVII activation which was several orders 
of magnitude less than FXa and FIXa.  However, the local concentration of α-thrombin during 
thrombin burst is very high.  Therefore, α-thrombin may still contribute to FVII activation in 
potential physiologic conditions, especially during the propagation phase of thrombin generation 
after clotting, when the vast majority of thrombin is produced.   
It has been shown that phospholipid membranes containing exposed PS are cofactors for 
FVII activation by FXa and FIXa (6,19,20).  Since the γ-carboxyglutamic acid-rich domains 
(containing multiple γ-carboxyglutamic acid residues, referred to as the Gla domain) of FXa and 
FIXa confer the membrane-binding capabilities of these proteins,  anionic phospholipids 
probably contribute to FVII activation by recruiting the enzymes, FXa and FIXa, onto the 
membrane surface through direct contacts with the Gla domains of these activators (21).  If so, 
then one should predict that meizothrombin, an intermediate in α-thrombin generation that 
retains the Gla domain, would interact directly with the phospholipid surface, thereby causing a 
higher rate of FVII activation compared to α-thrombin.  As expected, meizothrombin was 
roughly 3 to 8 times more efficient than α-thrombin in FVII activation in the presence of 
membrane (Table 8). 
Another potential activator of FVII is the TF/FVIIa complex.  The autoactivation of FVII 
by TF/FVIIa obeys a two-dimensional enzyme kinetic mechanism, with a k2D of 1.0 x 107 
m2/mol/s (Table 8).  The reaction rates are governed by the surface densities of TF/FVII(a) 
complexes in the membrane, rather than the molar concentrations of any of the reactants.  Even 
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though the catalytic activity of FVII autoactivation is considered to be low, the TF/FVII(a) 
complexes can easily encounter each other in the plane of the membrane with high TF density, 
consequently, allowing the reaction to occur at a faster rate.  Such unique mechanism suggests 
that FVII autoactivation should be rather cell type dependent: in cells with high TF density in the 
membrane, the reaction would be expected to take place at a much higher rate than on cells 
expressing lower levels of TF in the membrane.  However, even in the cell membrane with low 
TF density, clusters of TF molecules on certain subdomains of the membrane might permit the 
initiation of FVII autoactivation.  Notably, the rate of FVII autoactivation is dependent on the 
surface density of the TF/FVII(a) complexes on the phospholipid membrane, which therefore 
renders direct comparisons difficult with the rates of FVII activation by other enzymes.   
Our results also showed that FXIIa activated FVII, which was consistent with the 
previous publications (8,9).  However, the attempt of evaluating the rate of FVII activation by 
FXIIa failed in present experiments.  Within the first 1 min, 10 nM FVII (S344A) was activated 
by 50 nM or 100 nM XIIa to a certain level of FVIIa (S344A), about 2 or 8 nM, respectively 
(Fig. 14).  The extension of reaction time did not lead to a further increase in the concentrations 
of FVIIa generated.  The plot of time courses exhibits two distinct phases of FVII activation by 
FXIIa: a burst phase, reflecting initial activation of FVII; and a secondary phase, suggesting a 
further nonspecific digestion of FVIIa.  In consideration of the fact that the concentrations of 
FXIIa exceeded the concentration of FVII (S344A) in the present experiments, FXIIa had a very 
limited proteolytic activity toward FVII. 
The ability of FXIa to activate FVII was also examined.  Other activators mentioned 
above converted FVII to FVIIa by limited proteolysis at a single peptide bond (Arg152–Ile153).  
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In contrast, FXIa cleaved FVII (S344A) at positions which are different from the normal 
cleavage site, resulting in multiple fragments on SDS-PAGE gel (Fig. 15). 
 
Effect of TF on the activation of FVII 
It is known that TF is a critical cofactor for FVIIa enzymatic activity towards the protein 
substrates, FX and FIX (22,23).  However, previous data regarding the influence of TF on FVII 
activation has been controversial: several studies provided consistent evidence that TF markedly 
accelerated the conversion of FVII to FVIIa by FXa (24-27); in contrast, other studies concluded 
that TF did not influence FVII activation by FXa, either on carcinoma cells or on phospholipids 
(7,20).  To help elucidate this problem, the rates of FVII activation by each activator were 
evaluated in the presence of either 25 nM relipidated membTF, or 100 nM sTF, or no TF (Table 
8).  Our experimental data clearly support the conclusion that TF enhances the rate of FVII 
activation by several activators. 
In the present study, for each enzyme, the activation of FVII had a higher initial rate in 
the presence of sTF compared to the reaction with no TF, while membTF increased the rate of 
FVII activation further.  The only exception was that sTF failed to enhance FVII activation by 
FIXa relative to such reaction with no TF; whereas other activators, FXa, α-thrombin as well as 
meizothrombin, activated FVII 2 to 4 times better when sTF was present.  The known cofactor 
roles of TF in facilitating FVIIa enzymatic activity suggest how TF helps FVII activation, and 
why different patterns occurred in terms of influences of TF on FVII activation by different 
enzymes: TF may facilitate FVII activation, either 1) by helping FVII anchor on the membrane 
surface; or 2) by allosterically modulating the conformation of FVII via protein-protein 
interactions.  If so, then one should conclude that sTF fulfilled the latter role in FVII activation 
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by FXa, α-thrombin and meizothrombin; membTF fulfilled both roles, and enhanced the 
activation of FVII further.  Whereas for FIXa, sTF failed to enhance FVII activation, which 
suggests that TF affected the FVII activation primarily through the former role.  Hence, the 
activation of FVII by FIXa is less dependent on TF compared to other enzymes.  Under certain 
circumstances, e.g., in the circulation where TF and anionic phospholipids are usually rare, FIXa 
is more likely responsible for activating FVII in a TF-independent manner, therefore maintaining 
the basal levels of FVIIa in plasma. 
 
Lack of effect of FVa on the activation of FVII 
FVa is an essential cofactor to FXa in forming prothrobinase, and facilitating the 
activation of prothrombin to thrombin (28).  But 5 nM FVa did not enhance FVII activation by 
FXa in the present experiments (Fig. 16).  Our finding about the lack of effect on the FVII 
activation by FVa was in agreement with previous publication (6,19,20,29); however, the 
inhibitory effect of FVa suggested by Butenas et al. was not observed under the present 
experimental conditions (3).  
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TABLES AND FIGURES 
TABLE 7. Experimental conditions of FVII (S344A) activation by various activators. 
Reaction mixtures consisted of 10 nM FVII (S344A), varying concentrations of activators, 50 μM 20% 
PS/40% PE/40% PC phospholipids, in the presence of either 25 nM relipidated membTF, or 100 nM sTF, 
or no TF, shown in the table below.   
Activator 25 nM membTF 100 nM sTF No TF 
FXa 5 pM 25 pM 50 pM 
FIXa 0.1 nM 0.5 nM 1 nM 
α-thrombin 1 μM 5 μM 5 μM 
meizothrombin 0.1 μM 1 μM 1 μM 
TF/FVIIa*        15 nM membTF/ 0.5 nM FVIIa  
 
*FVII autoactivation by the TF/FVIIa complex obeys a two-dimensional enzyme kinetic mechanism (10). 
Reaction mixtures consisted of 10 nM FVII (S344A), 0.5 nM FVIIa, and 15 nM relipidated membTF with 
varying TF surface densities on 20% PS/80% PC vesicles.   
 
 
 
 
TABLE 8. Initial rates of FVII (S344A) activation by various activators.  
Activator membTF, nM/min/nM sTF, nM/min/nM No TF, nM/min/nM 
FXa 69.5 ± 4.1 33.4 ± 2.5 7.8 ± 2.2 
FIXa 3.2 ± 0.5 0.7 ± 0.3 0.8 ± 0.2 
α-thrombin 25.0 (± 5.6) × 10-5 1.8 (± 1.0) × 10-5 0.9 (± 0.1) × 10-5 
meizothrombin 20.7 (± 8.6) × 10-4 1.0 (± 0.8) × 10-4 0.3 (± 0.1) × 10-4 
TF/FVIIa*    k2D: 1.02 (± 0.07) × 107  m2/mol/s  
 
*FVII autoactivation obeys two-dimensional enzyme kinetic mechanism, yielding a two-dimensional 
second-order rate constant (10). 
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FIGURE 13. Evaluation of initial FVII (S344A) activation rate by FXa. (A) Western blot of temporal 
aliquots of incubation mixture, consisted of 10 nM FVII (S344A), 50 μM 20% PS/40% PE/40% PC 
phospholipids, 25 nM membTF, and 5 pM FXa. (B) The time course of FVIIa (S344A) formed based on 
Western blot and quantitation by densitometry. Initial rate of FVIIa (S344A) generation was calculated 
from a standard curve with purified FVIIa.  
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FIGURE 14. FVII (S344A) activation by FXIIa.  The time course of FVIIa (S344A) generation by 50 
nM (open circles) and 100 nM XIIa (filled circles) based on Western blot and quantitation by 
densitometry. 
 
 
   
FIGURE 15. FVII (S344A) activation by FXIa. Western blot of FVII (S344A) activation by FXIa. 1 μM 
FXIa was added to HBSPC buffer containing 10 nM FVII (S344A), 50 μM 20% PS/40% PE/40% PC 
phospholipids, and 25 nM relipidated membTF.  Aliquots of 30 μl were removed at 10, 20, 40, and 60 
min, subjected to SDS-PAGE followed by Western blot.   
min
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FIGURE 16. Lack of Influence of FVa on FVII (S344A) activation by FXa. FXa was incubated with 
10 nM FVII (S344A), 50 μM 20% PS/40% PE/40% PC phospholipids, and either 25 nM relipidated 
membTF (A), 100 nM sTF (B), or no TF (C), in the presence (open circles) or absence (filled circles) of 5 
nM FVa. 
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